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1 Introduction 
1.1 Lung Cancer 
1.1.1 Statistics 
According to the reports of the World Health Organization (WHO), lung cancer is leading 
the cancer-related death cases worldwide. Out of 8.2 million cancer deaths cases, 12% were 
related to lung cancer followed by liver and stomach cancer (Fig. 1.1a). Despite the 
enormous research conducted on lung cancer and the development of new therapies, the 5-
year survival is still modest being only 5.8 % for lung cancer compared to 48% for all cancers 
(Fig. 1.1b)1. In women, lung cancer occupies the third place as a common cause of cancer 
incidence after breast cancer and cervical cancer and second most common cause of cancer 
mortality. However, in the developed countries there are no differences between both 
genders2. 
 
Figure  1.1 Cancer Statistics 2012.  Worldwide statistics of both genders representing a) Cancer-related death 
cases worldwide, b) Percentage of 5-year prevalent adult cancer cases. (Adapted from WHO report, Globocan 
IARC, 2012)2. 
 
Differences in incidence, survival and deaths caused by lung cancer vary according to 
world region, development state, lifestyle, gender and age. Like many other cancer types, 
lung cancer incidence increases with increasing age probably due to accumulation of 
mutational changes or environmental hazards. The main challenge of lung cancer is that 
most cases are presented at advanced at late stage of the disease and therapy often 
encounters chemoresistance2. 
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1.1.2 Classification of lung cancer 
For pathological diagnosis, lung cancer is classified via histological and cytological 
approaches into small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), which 
is subdivided into adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell lung 
cancer (LCLC). These are the main histologic types of lung cancer but there is continuous 
debate on better and more detailed classification3. Results of several studies the 
classification of tumours based on their driver mutations and not merely based on their 
histological types4. The importance of a thorough classification of lung cancer relate to the 
impact of cancer type on choosing the suitable therapy. Where EGFR tyrosine kinase 
inhibitors (TKIs) or pemetrexed-based therapy regimens are suitable for patients with ADC 
having EGFR mutation, patients with SCC are not eligible for these therapies3.  
NSCLC accounts for over 85% of all lung cancer cases and is predominantly represented 
by ADC (about 50%) and SCC (40%). Besides the morphological structure of the tumour 
specimen, specific biomarkers are used to identify the cancer type. ADC usually has a 
glandular structure and expresses thyroid transcription factor 1 (TTF1) and keratin 7 (KRT7). 
On the other hand, SCC expresses cytokeratin 5 and cytokeratin 6 and/or the transcription 
factors SRY-box 2 (SOX2) and p635. Table 1.1 illustrates main features of ADC and SCC. 
Table  1.1 Main characteristics of lung adenocarcinoma and squamous cell carcinoma6, 7. 
 Adenocarcinoma (ADC)  Squamous Cell Carcinoma (SCC) 
Origin distal airways, alveolar type II 
cells 
 proximal airways in the vicinity of 
pseudostratified columnar 
epithelium of tracheal and upper 
airways 
Biomarkers TTF1 (NKX2-1), KRT7   Cytokeratin 5, Cytokeratin 6, SOX2, 
p63 
Common 
mutations 
KRAS, BRAF, EGFR, HER2, MET, 
FGFR1, FGFR2 
 DDR2, FGFR1, FGFR2, FGFR3, 
Several genes in PI3K pathway 
 
ADCs originate from secretory alveolar type II (ATII) cells and thus develop in distal 
airways, whereas SCCs form in proximal airways in the trachea and upper bronchial 
epithelium. SCLC on the other hand arises from neuroendocrine cells and is considered the 
most aggressive form6. The cell of origin of lung cancer assumingly determines the tumour 
type, at least from studies in murine models with specific genetic alterations in respective 
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cells8. Cancer-initiating cells often known as cancer stem cells were identified in the lung in 
the bronchioalveolar duct junction (BADJ). This region harbours a cell population expressing 
both Clara cell marker (CCSP) and ATII cell marker, surfactant protein C (SPC), along with 
possessing stem cell markers like Sca-1 and CD34. They were termed BASCs, 
bronchioalveolar stem cells8. Recently, Xu et al. provided evidence that ATII cells are the cell 
of origin of lung adenocarcinoma using a mouse model with K-Ras mutation9. 
With increasing data on the molecular changes identified within resected tumour 
samples, many studies plead for the integration of genomic information into cancer 
classification, especially for the metastatic cancers of unknown primary origin10.   
1.1.3 Aetiology of lung cancer 
The lung is a unique organ with multicellular diversity making lung cancer a multifaceted 
disease. Several environmental factors were reported to affect the incidence of lung cancer 
including air pollution and occupational hazards. Cigarette smoke is on the top of this list and 
was reported in correlation with SCC rather than ADC. However, 10% of lung cancer cases 
occur in patients with no smoking history11. This indicates that there are other 
predispositions for lung cancer development.  
Increasing evidence support the impact of genetic susceptibility on increasing cancer 
risk. Compared to many cancer types, lung cancer was reported to show high mutational 
burden assumingly due to exposure to carcinogens as air pollutant and cigarette smoke7. 
Nevertheless, ADC patients with no smoking history often show mutations of EGFR gene and 
thus respond to TKIs though they develop resistance. On the other hand, smokers frequently 
develop KRAS mutations and do not respond to TKI therapy. In a genome-wide study on 188 
primary lung ADC samples, a set of 26 genes was identified with a high rate of mutations in 
tumour suppressor genes (TP53, CDKN2A, and STK11) as well as known oncogenes (KRAS, 
EGFR and NRAS). It is worth mentioning that EGFR and KRAS mutations were mutually 
exclusive12. 
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1.1.4 Oncogenes KRAS and C-RAF 
KRAS mutations were detected in about 30% of ADC cases13. Most mutations of KRAS 
identified in smokers are transversions (G T or G C) in a single amino acid in codon 12. 
KRAS belongs to the RAS oncogene family together with HRAS and NRAS, which are small 
GTPases serving in the mitogenic cascade (Fig. 1.2). The signalling is then mediated through a 
series of kinases forming the RAF/MEK/ERK cascade14. An interesting study conducted by 
Blasco et al. using K-Ras+/G12V mice concluded that the elimination of both Erk1 and Erk2 is 
required to block tumour development, whereas deletion of B-Raf showed no significant 
effects on tumour development. Instead, C-Raf expression was essential to mediate K-Ras 
signalling and form tumours15. 
 
Figure  1.2 RAF signalling pathway. Schematic representation of the Raf signalling through the extracellular 
signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) cascade. Growth stimuli to the cell 
activate Ras protein which then activates C-RAF inducing sequential downstream phosphorylation steps. At the 
end of the cascade phosphorylated ERK can phosphorylate both nuclear and cytosolic targets resulting in 
proliferation (Adapted from Meister et al., 2013)14. 
 
More than two decades ago Rapp and colleagues identified C-RAF as the mammalian 
homologue of v-raf oncogene16. The name RAF derives from the ability of the viral 
homologue to induce rapidly accelerated fibrosarcomas in mice17. Several studies followed 
showing the role of C-RAF in lung development and carcinogenesis. Though activation 
mutations in C-RAF were reported, e.g. E478K, S427G and I448V, their significance still has to 
be established as they were rarely reported in human cancers. However, targeting C-Raf 
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overexpression in the lung demonstrated transforming potential. Rapp et al. established a 
lung tumour mouse model with constitutively active C-RAF, termed C-Raf BxB. These mice 
developed benign adenomas in the lung though no metastasis was detected18.  
Sorafenib is a C-Raf kinase inhibitor that acts on wildtype C-Raf and B-Raf as well as on 
oncogenically activated B-Raf kinases. In addition to its antiproliferative effects, like many 
kinase inhibitors, sorafenib had several off target effects. Its anti-angiogenesis activity was 
shown to be stronger acting through the inhibition of VEGFR kinases. Furthermore, sorafenib 
increased apoptosis in preclinical models of hepatocellular carcinoma (HCC) and was later 
used clinically in a phase III trial in both HCC and renal cell carcinoma19. In NSCLC, sorafenib 
showed anti-tumour activity but was suggested only for treatment of a subset of patients 
and in conjunction with other inhibitors20.   
As C-Raf is relatively on the top of the mitogenic cascade it can affect many downstream 
signalling pathways. NF-ƙB signalling was found to be activated indirectly by C-Raf through 
MEKK1 which goes in line with the increased inflammatory signals observed in many 
cancers21.   
1.2 NF-ƙB signalling pathways & the role in cancer 
1.2.1 The transcription factor family NF-ƙB 
Nuclear Factor-ƙB was first discovered in 1986 by Sen and Baltimore as DNA-binding 
protein in B cells22. It was first thought to play a role only as a regulator of ƙB light chain 
expression. Meanwhile, intense research showed that NF-ƙB is expressed ubiquitously in 
almost all cell types and that it is a pleiotropic transcription factor having its specific NF-ƙB 
binding sites at the promoters of a wide range of genes23, 24. 
In mammals, NF-ƙB transcription factor family consists of five proteins which form 
various combinations of homo- and heterodimers with each other. They all share a 
conserved 300 amino acids long Rel homology domain (RHD) at their amino terminal. RHD is 
required for their dimerization, nuclear translocation, DNA binding and interaction with IƙB 
proteins. The carboxyl end of the RHD is thought to be responsible for dimerization and 
interaction with IƙBs, whereas its amino terminal part facilitates the binding of NF-ƙB 
transcription factors to specific NF-ƙB consensus sequence (5’-GGGpuNNPyPyCC-3’) present 
in the promoter region of various regulated genes25. 
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Three members of the family, RelA (p65), RelB and c-Rel (also known as Rel), have a 
transactivation domain (TAD) at their carboxyl terminal. The other two members, p105 (NF-
ƙB1) and p100 (NF-ƙB2), lack such domain but instead have a sequence of 5-7 ankyrin repeat 
motifs at their carboxyl terminal. They are precursors for p50 and p52, respectively, which 
can bind actively to the DNA. Due the presence of ankyrin repeat motifs, p100 and p105 are 
also considered inhibitors of ƙBs as they block the interaction with the DNA (Fig. 1.3a).  
NF-ƙB activation is a relatively rapid process, as in the unstimulated state, the 
transcription factor dimers are sequestered in the cytoplasm being bound to IƙB proteins. 
IƙBs are a family of 5 members, with IƙBα, IƙBβ and IƙBɛ being the most studied members. 
The C-terminal portions of p105 and p100 were historically termed IƙBγ and IkBδ, 
respectively. BCL-3 is an unconventional IƙB protein as it contains a transactivation domain 
to interact with the DNA and mediate transcriptional activity26. It was reported that IƙB 
proteins suppress NF-ƙB activity not just by masking the nuclear localization signal (NLS) and 
preventing binding to the DNA but also by facilitating the nuclear export of NF-ƙB active 
dimers26, 27. 
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Figure  1.3 Members of the NF-ƙB transcription factor family. a) NF-ƙB subunits, RELA (p65), RELB and REL have 
rel homology domains (RHD) at the N-terminal which is important for dimerization and DNA binding. At the C-
terminal transactivation domains (TAD) mediate transcriptional activity. NF-ƙB1 (p105) and NF-ƙB2 (p100) 
possess only RHD in addition to Ankyrin repeats (green boxes) that allow their function as IƙB proteins. p105 
and p100 are proteolytically processed (at black arrow) to generate p50 and p52, respectively. Main 
phosphorylation sites of RelA (p65) and p50 are indicated by a green circle with P. b) IKK complex consists of 
IKK1 and IKK2 with kinase domain whereas NEMO lacks enzymatic activity. They interact with NEMO via their 
NBD (NEMO binding domain. LZ (leucine zipper); HLH (helis-loop-helix); CC (Coiled coil); ZF (zinc finger). 
(Adapted from Oeckinghaus and Ghosh25, Perkins28 and Hoesel and Schmid26).  
 
Within this transcriptional system different NF-ƙB members show specificity by 
preferential binding to specific DNA-binding consensus sequences as summarized in Table 
1.229. Hence, distinct dimers can activate certain target genes. This preferential control is 
also stimulus dependent and activates different signalling pathways. 
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Table  1.2 NF-ƙB subunits and their binding sites 30, 31 
NF-ƙB subunit DNA-binding consensus sequence 
General 5’-GGGpuNNPyPyCC-3’ or  
5’- GGG-ATTTCC-3’ 
RelA/p65 GGGGTATTTCCC 
p50 GGG-AT--CCC 
c-Rel GGGGTATTTCC 
RelB GGGGTATTTCC 
p52 GGGGTATTTCC 
 
1.2.2 Canonical and non-canonical pathways 
Activation of NF-ƙB is mediated by inhibitory ƙB kinases (IKKs), IKK1 and IKK2 also known 
as IKKα and IKKβ, respectively. IKKγ is a regulatory subunit commonly known as NEMO (NF-
ƙB essential modulator) which lacks kinase activity but is required for the formation of the 
complex. The kinases IKK1 and IKK2 contain a kinase domain at the amino terminal, a leucine 
zipper to allow dimerization of the kinases and helix-loop-helix domain supporting the kinase 
activity (Fig 1.3b). The complex is activated by phosphorylation at two serine residues; 
Ser177 and Ser181 for IKK2 and Ser176 and Ser180 for IKK1. Several upstream kinases can 
activate the IKK complex, e.g. NIK (NF-ƙB inducing kinase), TAK1 (TGFβ-activating kinase 1), 
MEKK1 and MEKK3. In addition, mutual autophosphorylation within the IKK dimers can be 
initiated in response to stimulus or proximity-induced conformational changes mediated by 
NEMO32.  
The canonical NF-ƙB signalling pathway is triggered by inflammatory cytokines, e.g. 
TNFα, pathogen-associated molecules, e.g. LPS, antigen receptors, and Toll-like receptors 
(TLRs). The trimeric complex of IKK1, IKK2 and NEMO phosphorylates IƙBα so that ubiquitin 
binds to the inhibitor and is degraded by the proteosomal machinery freeing p50/p65 for 
nuclear translocation. On the other hand, the non-canonical or alternative NF-ƙB activation 
pathway is activated by other receptors including lymphotoxin β-receptor (LTβR), receptor 
activator for nuclear factor kappa B (RANK) and CD40. This activation is mediated via NIK 
which mainly phosphorylates IKK1 dimer. Subsequently, p100 is either partially digested into 
p52 or ubiquitinated for degradation. Generation of p52 often encourages the dimerization 
with RelB to target a distinct set of genes (Fig. 1.4). Finally, atypical activation pathways exist 
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in response to genotoxic stress where ATM kinase activates IKK complex leading to the 
ubiquitination of NEMO26.  
 
 
Figure  1.4 NF-ƙB signalling pathways. In the canonical pathway, stimuli lead to the phosphorylation of IKK 
complex which phosphorylated IƙBα. This is followed by ubiquitin mediated degradation of IƙB and release of 
p50/RelA to translocate to the nucleus. In the non-canonical alternative pathway, IKK1 dimer is phosphorylated 
by NIK and consequently phosphorylates p100 to be partially proteasomally degraded releasing p52/RelB to 
the nucleus. (Adapted from Jost et al., 2007)33. 
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1.2.3 Posttranslational modifications of NF-ƙB subunits 
Owing to its seminal role in various biological processes, NF-ƙB is tightly regulated at 
different levels. Besides the regulatory IƙB proteins, NF-ƙB subunits themselves are directly 
regulated by posttranslational modifications. Phosphorylation of RelA/p65 was reported 
both in the RHD at five sites (Ser205, Thr254, Ser276, Ser281, and Ser311) as well as in the 
TAD at seven residues (Thr435, Ser468, Thr505, Ser529, Ser535, Ser536, and Ser547)34. 
Depending on the stimulus and modification site, NF-ƙB transcriptional activity is regulated 
by a different mechanism. The p50 subunit also undergoes posttranslational modifications. 
Hou et al. identified three serine residues (Ser65, Ser337, and Ser342) in the RHD that are 
phosphorylated to regulate the ability of p50 to bind to the DNA35. Table 1.3 summarizes the 
role of the main modifications on p50 and RelA/p65.   
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Table  1.3 Main posttranslational modifications of NF-ƙB subunits and their significance 
NF-ƙB subunit Site/Location Mediated by Effect Reference 
RelA/p65      
Phosphorylation S205, 
S281/RHD 
Several kinases • Regulate subcellular 
localization 
• Not required for IƙBα binding 
Hochrainer 
et al., 
200736 
 S276/RHD Protein kinase 
A, MSK1 
• Critical for the interaction 
with c-activators  
• PKA phosphorylation 
enhances recruitment of 
p300 and CBP 
• Decreases HDAC1 affinity for 
p65 
Yang et al., 
200337 
 S311/RHD 
vicinity 
Protein kinase 
Cζ (PKCζ) 
• Essential for the interaction 
with CBP 
• Needed for the recruitment 
of RNA polymerase II to 
target gene promoters 
• Mediated by TNFα 
 
Duran, et 
al., 200338  
Hochrainer 
et al., 
201334 
 S529/TAD Casein kinase II  Yang et al., 
200337 
     
 S536/TAD IKK2, TAK1-
TAB1 
Increases interaction with p300 
for acetylation at K310 
Yang et al., 
200337 
  Ribosomal S6 
kinase 1 (RSK1) 
Stimulated by p53 Bohuslav et 
al., 200439 
     
Acetylation K122, K123  Reduce DNA binding but 
facilitate p65-IƙBα interaction 
Hochrainer 
et al., 
200736 
 K218, K221 p300 & 
deacetylated 
by HDAC3 
• They impair p65-IƙBα 
interaction and thus nuclear 
export 
• HDAC3 terminates NF-ƙB and 
allows nuclear export of p65-
IƙBα 
 
p50     
Phosphorylation S20 DNA-
dependent 
protein kinase 
Increases DNA binding as seen 
on VCAM1 promoter 
Ju et al., 
201040 
 S65, S337, 
S342 
Protein kinase 
A 
Increases DNA binding but 
doesn’t affect dimerization 
Hou et al., 
200335 
Acetylation     
 K431, K440, 
K441 
p300 Potentiates interaction of 
p50/p65 upon TNFα or LPS 
stimulation to sustain activity 
Deng et al., 
200341 
Deng et al., 
200342 
Furia et al., 
200243 
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1.3 NF-ƙB cellular functions 
Activation of NF-ƙB results in the active transcription of many genes playing a role in vital 
biological processes. Many of the pleiotropic functions of NF-ƙB were correlated to 
neoplastic transformation.  
1.3.1 NF-ƙB in immune and inflammatory responses 
Different genes involved in both innate and adaptive immune response are target genes 
of NF-ƙB, e.g. IL1, IL6, IL8, TNFα, GM-CSF, G-CSF, MCP1, and RANTES. Selective deletion of 
IKK2 in murine lung epithelial cells resulted in delayed Th17 and B cell responses and thus 
delayed fungal clearance in a model of pneumocystis44. In a study on patients with severe 
combined immunodeficiency (SCID), patients carried a loss of function mutation in IKK2 gene 
which was reflected in the presence of almost naïve T cells and the lack of regulatory T cells. 
Their isolated immune cell failed to respond to stimulation by cytokines and mitogens45. 
Even a developmental function for NF-ƙB signalling was identified in the maturation of T-
lymphocytes46.  
1.3.2 NF-ƙB and cell cycle regulation and apoptosis 
Cell growth is regulated by different signalling pathways including NF-ƙB. Entry into the S 
phase of the cell cycle is activated by G1 cyclins, especially by cyclin D family. NF-ƙB directly 
binds to the ƙB site on the cyclin D1 promoter leading to its transcriptional activation. 
Besides it activated c-myc encouraging the entry into the cell cycle47. 
NF-ƙB also plays a role in cell survival and escape from programmed cell death. It 
induces the expression of several anti-apoptotic proteins involved in the intrinsic death 
signalling pathway like Bcl-2 family, members of the inhibitors of apoptosis (IAP) family, p53, 
and suppresses JNK by inducing JNK inhibitors such as XIAP. It was shown that mouse 
embryonic fibroblasts lacking IKK2 showed increased cell death and stabilized p53 in 
response to chemotherapeutic agents corroborating to the role of NF-ƙB in drug 
resistance48. Furthermore, deletion of RelA in fibroblasts sensitizes cells to TNF-α induced 
apoptosis49. 
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1.3.3 NF-ƙB in cell adhesion and angiogenesis 
The role of NF-ƙB outranges proliferation to encourage cell mobility and angiogenesis. 
NF-ƙB induces the expression of various cell adhesion molecules, e.g. matrix 
metalloproteinases (MMP2 and MMP9), vascular cell adhesion molecule (VCAM-1), and 
intracellular cell adhesion molecule (ICAM-1). The target genes scope of NF-ƙB also covers 
diverse genes regulating endothelial cell growth, vasodilation via inducible nitric oxide 
synthase (iNOS) and angiogenesis  via vascular endothelial growth factor (VEGF)47. 
 
1.4 IKK2 and NF-ƙB in lung carcinogenesis 
On account of the aforementioned cellular functions of NF-ƙB in cell proliferation, 
promotion of migration and invasion as well as inhibition of apoptosis, it is not surprising 
that NF-ƙB plays a significant role in cancer development. Though few genetic alterations 
were detected amongst the NF-ƙB family, several mutations were detected in their upstream 
activators. Besides, the contribution of an inflammatory microenvironment to tumour 
progression made inflammation the seventh hallmark of cancer50.   
1.4.1 Expression of NF-ƙB in different cancer types 
NF-ƙB activation was observed in lymphoid malignancies as well as in most solid 
tumours. NF-ƙB activation was reported in MALT lymphomas, diffuse large B-cell lymphoma 
(DLBCL), and multiple myeloma. Other lymphoid cancers resulting from viral tumour viruses, 
like Epstein-Barr virus, Kaposi Sarcoma-associated herpes virus or human T-cell lymphoma 
virus, also reveal NF-ƙB activation51, 52.   
In some cancer types, presence of persistent inflammation paves the road to 
tumorigenesis, a concept termed cancer-related inflammation53. Vlantis et al. showed in a 
mouse model that persistent genetic activation of NF-ƙB signalling in intestinal epithelial 
cells is sufficient to induce intestinal tumours54. In another colitis-associated cancer model, 
Greten et al. show that deletion of IKK2 in both epithelial and myeloid cells could diminish 
tumour formation55. 
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In prostate cancer, activation of NF-ƙB was correlated with tumour progression as well 
as with chemoresistance51. Hypoxic prostate cancer cells, which are resistant to therapy, 
express higher levels of IL-8 as a result of NF-ƙB activation and thus promote cell survival56.  
In lung cancer, it was shown that in tumours with PTEN inactivation, NF-ƙB promotes cell 
invasiveness and anchorage-independent growth mediated via PI3K/AKT pathway57.  
Glioblastoma tumours often show a deletion of NFKBIA which is mutually exclusive with 
EGFR amplification58. Activation of NF-ƙB was also observed in head and neck squamous cell 
carcinoma and was correlated with metastasis59, in hepatocellular carcinoma51 and in breast 
cancer by promoting tumour-initiating cells60. 
1.4.2 Targeting NF-ƙB for cancer therapy 
It is well established that NF-ƙB promotes proliferation and survival of cancer cells, 
supports angiogenesis and thus metastasis, evades adaptive immunity and alters responses 
to chemotherapy. Thus, cancer-related inflammation is an appealing target for novel 
therapeutic strategies and even diagnosis61. 
The benefits of targeting NF-ƙB were observed in several cancers either using NF-ƙB 
inhibitors solely or in combination with other therapies. In multiple myeloma, there is often 
activating mutation in NIK which mainly activates the alternative NF-ƙB pathway. Selective 
NIK inhibitors were selectively toxic for cells with such mutations. Combination therapy of 
NIK inhibitors and other chemotherapeutic agents provide a promising therapeutic strategy 
for multiple myeloma62.  
Targeting NF-ƙB sensitizes cancer cells to chemotherapy in NSCLC63 and in breast 
cancer64. Combined treatment of lung cancer cell lines with SAHA, an HDAC inhibitor, and 
Bay11-7085, a selective IKK2 inhibitor, was more effective than either drugs alone65. In 
support with these data, Bay11-7085 increases the therapeutic effectiveness of bortezomib, 
a proteasome inhibitor, in ovarian cancer66.  These studies emphasize the importance of 
acquiring more insight into the regulation of NF-ƙB. 
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1.5 Epigenetic control via NuRD complex in lung cancer  
The nucleosome and remodelling deacetylase complex was first discovered in 1998 in 
different species. It is a chromatin remodelling complex having important roles in chromatin 
assembly, transcription, and genomic stability. Initially, it was called Mi-2 complex but now 
the common name is NuRD complex67.  
1.5.1 Members of the NuRD complex 
The NuRD complex comprises mainly six core subunits; of which only two possess 
enzymatic activity and the rest act as scaffold proteins and facilitate the interaction between 
the complex members, transcription factors and the DNA. Chromodomain-helicase-DNA-
binding protein 3 and 4 (CHD3 and CHD4, also known as Mi-2α and Mi-2β, respectively) have 
ATPase activity to unwind the chromatin so that it is accessible to histone deacetylase 1 and 
2 (HDAC1 and HDAC2). The other structural proteins are metastasis-associated protein 1, 2 
and 3 (MTA1, MT2, MTA3), retinoblastoma binding proteins 4 and 7 (RBBP4 and RBBP7, also 
known as RbAp46 and RbAp48, respectively), methylated CpG-binding protein 2 and 3 
(MBD2 and MBD3) and GATAD2a (p66α) or GATAD2b (p66β)68, 69 (Fig. 1.5). According to 
Smits et al. who studied the stoichiometry of the NuRD complex, the complex comprises one 
subunit of CHD3 or CHD4, one HDAC1 or HDAC2, three subunits of MTA1/2/3, one MBD2 or 
MBD3, six RbAp46/48, and two GATAD2a/b67.  
CHD3 and CHD4, the Mi-2 protein homologues, were first identified as an autoantigen in 
dermatopolymyositis.  They have a molecular mass of 220kDa and their ATPase activity is 
stimulated by chromatin rather than by naked DNA or histones. Through their PHD domains 
they bind to H3 tails. By releasing energy from ATP, they mediate chromosome remodelling 
making DNA more accessible to HDACs and to RNA polymerases69. 
HDAC1 and HDAC2 are members of class I histone deacetylases. They are 55kDa in size 
and share 83% sequence homology, which is reflected in their redundant functionality. 
Owing to their deacetylation activity they were related to transcriptional repression 
especially of genes involved in cell proliferation. However, knockdown of HDAC1 or HDAC2 
lead to the downregulation of several genes indicating a dual role in gene regulation70, 71.  
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Figure  1.5 Core components of the NuRD complex. Schematic representation of a) enzymatic subunits CHD3/4 
(chromodoamin-helicase-DNA-binding protein) and HDAC1/2 (histone deacetylase) and b) structural subunits 
MTA1/2/3 (metastasis-associated proteins), MBD2/3 (methyl-CpG-binding domain), GATAD2A/B (GATA zinc 
finger domain containing 2A/B) and RBAP46/68 (retinoblastoma associated protein) showing their respective 
protein domains. BAH (bromo-adjacent homology); Chromo (chromatin organization modifier); ELM (Egl-27 
and MTA1 homology); E repeats (poly glutamate); GR repeats (glycine-arginine rich region); PHD (plant 
homodomain); RB binding (binding domain to RbAp proteins); SANT (Switching-defective protein 3, Adaptor 2, 
nuclear receptor co-repressor, transcription factor IIIB); TRD (transcription repression domain); WD repeats 
(repeats of WD40); ZnF (zinc finger).(Adapted from Torchy et al., 2015; Allen et al., 2013; and from Lai et al., 
2011)68, 69, 71 
MTA family comprises three members where MTA1 and MTA2 are more functionally 
related than MTA3. Their molecular masses are 80, 70 and 65kDa for MTA1, MTA2 and 
MTA3, respectively. They lack intrinsic enzymatic activity but they contribute to the 
assembly and stabilization of the NuRD complex via their different domains. Though the 
exact functional roles of their domains are not fully elucidated yet, some functional roles are 
assumed from similar proteins. The BAH domain is involved in protein-protein interactions, 
whereas SANT and ELM were reported to interact with HDACs wrapping around their 
catalytic domain. In addition, SANT domain interacts with unmodified histone tails. The zinc 
finger GATA-like domain could be responsible for direct interaction with the DNA72, 73.  
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MBD2 and MBD3 are the smallest subunit of the NuRD complex (43 and 33kDa, 
respectively). MBD2 has a transcription repression domain (TRD) and binds mainly to 
methylated CpG islands at transcription start sites, whereas MBD3 binds to unmethylated 
DNA suggesting a role in active transcription74. 
Retinoblastoma-associated proteins RbAp46 and RbAp48 are mainly responsible for 
protein-protein interaction through their WD40 protein repeats. These are a structure motif 
of 40 amino acids forming a ß-propeller conformation for recognition at protein-protein or 
protein-DNA interfaces. GATAD2 proteins were shown to interact and co-localize with MBD2 
and MBD3. It is reported that other subunits could also bind and interact with the NuRD 
complex depending on the biological context71.  
1.5.2 Biology and function of NuRD complex in cancer 
Initially, the function of the NuRD complex was related only to transcription repression. 
However, there is increasing evidence of its role both as repressor and gene activator. In 
cancer, the NuRD complex was recruited by oncogenes as TWIST to suppress E-cadherin and 
thus drive the cells into epithelial-mesenchymal transition (EMT)69. Another mechanism is by 
altering tumour suppressor genes which are often methylated in cancer. The NuRD complex 
was found to be recruited to these sites mediating further silencing of the tumour 
suppressor genes.   
Moreover, the NuRD complex can directly interact with other proteins and transcription 
factors, e.g. HIF1α and p53. In breast cancer MTA1 recruits HDAC1 to acetylated HIF1α thus 
leading to its stabilization. HIF1α stabilization activates various genes promoting 
angiogenesis and metastasis68, 71. In case of p53, the NuRD complex deacetylates p53 leading 
to its inactivation and cells are driven to uncontrolled cell growth and resistance to 
apoptosis75. 
1.5.3 MTA2/NuRD in cancer 
MTA1 was first characterized in rat mammary adenocarcinoma. Despite their structural 
similarity, MTA1 and MTA2 vary functionally from MTA3. In DLBCLs MTA3 mediates BCL-6-
dependent repression of genes associated with plasma cell differentiation. In addition, MTA3 
is induced by oestrogen and is a transcriptional target of oestrogen receptor (ERα). However, 
it is highly expressed in normal ducts to maintain healthy differentiated epithelial phenotype 
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by repressing SNAI1, a transcription factor promoting EMT. MTA3 also represses Wnt4 and 
subsequent Wnt target gene expression in mammary epithelial cells76. 
On the contrary, MTA1 and MTA2 correlate with cancer progression and poor prognosis 
in different cancer types including breast cancer, colorectal cancer, gastric cancer, 
hepatocellular carcinoma and lung cancer. In lung cancer, Liu et al. showed that nuclear 
MTA2 correlates with lung cancer cell proliferation, tumour size, and lymph node metastasis 
making it a potential candidate for molecular staging77. Besides, MTA2 overexpression was 
correlated with tumour progression and poor prognosis in a study conducted on patients 
with oesophageal squamous cell carcinoma78. 
At this stage it is worth mentioning that MTA1 and MTA2 localize primarily in the nucleus 
though cytoplasmic localization was also detected. In embryonic studies MTA1 was mainly 
identified in the cytoplasm indicating its role in embryogenesis whereas adult cells show 
nuclear localization indicating a shift in its functional role to adult cell regulation79.  
The role of the NuRD complex and its members in the outcome of cancer is gaining 
attention yet it requires deep functional insight to elucidate its differential regulation in 
different cellular contexts. Being a major epigenetic regulator, further investigations are 
required to delineate the interaction of the NuRD complex with transcription factors. 
  
Introduction 
 
19 
 
1.6 NF-ƙB and epigenetic control 
NF-ƙB is capable of mediating a plethora of effects within the cell which makes its 
intricate control a necessity. Increasing evidence show the epigenetic regulation of NF-ƙB 
especially in the context of tumorigenesis.  
Several reports provide evidence of the interaction of NF-ƙB and the chromatin 
remodelling machinery. Akirin, which regulates NF-ƙB-dependent transcription, mediates the 
interaction between NF-ƙB and SWI/SNF complexes resulting in the regulation of several 
genes related to the innate immune response. IƙB-ζ forms a complex including p50 and 
SWI/SNF together with Akirin2 and upon stimulation the complex is recruited to the 
promoter of certain genes, e.g. Il6 and Il12b to activate them80.  
In breast cancer, NF-ƙB regulation was recently linked to damaged DNA-binding 2 protein 
(DDB2), which is a negative regulator of migration and invasion. Overexpression of DDB2 
decreases invasiveness and metastasis via reduction of MMP9 levels. Therefore, metastatic 
breast tumour cells lacked DDB2 expression compared to their non-metastatic counterparts. 
Strikingly, DDB2 induced IƙBα expression which consequently decreased NF-ƙB activity81. 
Additionally, members of NF-ƙB family can act themselves as epigenetic regulators of NF-
ƙB-dependent gene activation. The homodimer of p50 interacts with HDAC1 to inhibit pro-
inflammatory genes82. This mechanism was also reported in LPS tolerance83. A study in acute 
myeloid leukaemia suggests that C/EBP displaces HDACs from p50 homodimers and thus 
driving the activation of anti-apoptotic genes84.    
Hitherto, the epigenetic regulation of NF-ƙB is an intriguing conundrum that requires 
more investigation. Unravelling the underlying mechanisms and the contributing complexes 
regulating NF-ƙB in cancer would aid in the development of novel but specific therapeutic 
modalities.   
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2 Aims  
The role of NF-ƙB in lung cancer showed puzzling effects despite extensive studies 
indicating the need for further efforts to elucidate the molecular activation and regulation of 
NF-ƙB. 
The aim of the following work is to study the role of NF-ƙB signalling via IKK2 in the 
pathogenesis of lung adenocarcinoma and to study the epigenetic control of NF-ƙB through 
MTA2/NuRD complex.  
The study aimed at investigating the role of IKK2/NF-ƙB in lung tumour development by: 
• Comparison of different cancer cell lines for NF-ƙB expression and activity 
• Studying the effect of LPS and TNFα as stimuli  
• Testing of IKK2 inhibitors 
• Generation of compound transgenic mice with IKK2 constitutive activation or IKK2 
downregulation in SpC C-Raf BxB tumour mouse model (SpC rtTA/Tet-O-IKK2CA/SpC 
C-Raf and SpC rtTA/Tet-O-IKK2DN/SpC C-Raf) 
• Evaluation of tumour burden after long term induction with doxycycline for 12 
months 
• Investigating the changes in immune cell repertoire in compound mice 
• Isolation of alveolar type II cells to study signalling changes regulated by IKK2  
MTA2/NuRD hypothesized regulation of NF-ƙB is addressed by: 
• Overexpressing MTA2 in cancer cell lines and assessing the NF-ƙB activity 
• Studying the interaction between MTA2/NuRD complex and NF-ƙB 
• Evaluating the effect of knocking down MTA2 by shRNA on tumour development in a 
xenograft mouse model 
 
Materials & Methods 
21 
 
3 Materials and Methods 
3.1 Cell biological methods & cell culture 
3.1.1 Cell cultivation 
Human lung adenocarcinoma cells (A549, A427, Colo699, H1650, H2122) BEAS-2B 
(human bronchial epithelial cells), human embryonic kidney cells (HEK293T) and mouse 
Lewis lung carcinoma (LLC1) were obtained from ATCC. A549 and HEK cells were cultured in 
DMEM medium supplemented with 10% foetal calf serum (FCS, Th. Geyer, Germany) and 1% 
penicillin/streptomycin (100 I.U./ml and 100µg/ml, respectively, Gibco® by Life 
Technologies, Germany). A427, Colo699, H1650, H2122 and LLC1 were cultured in RPMI 
medium supplemented with L-glutamine, 10% FCS and 1% penicillin/streptomycin. BEAS-2B 
cells were cultured in DMEM/F-12 (Dulbecco's Modified Eagle Medium/Ham's F-12) medium 
using 5% FCS, 1% penicillin/streptomycin. All cells were cultured at 37°C and 5% CO2 
(HERAcell 150i, Thermo Scientific) according to manufacturer’s recommendations. 
When cells reach 80-90% confluency, they were subcultured and split in a ratio of 1:3 to 
1:6 depending on the density needed and cell type. Medium was aspirated, cells were 
washed with 1x phosphate buffered saline (1xPBS, Gibco® by Life Technologies) and 
incubated with 1x trypsin (Thermo Fisher, Germany) for 3-5minutes at 37°C until cells 
detach. To stop the trypsin activity, media with FCS or FCS alone was added to the cells and 
the cell suspension was collected and centrifuged at 300xg for 5minutes. Cell pellet was then 
resuspended in fresh media and cells were plated at the desired ratio. 
 For freezing purposes, cells were trypsinized and cell pellet was resuspended in freezing 
medium containing 10% dimethylsulfoxide (DMSO, Sigma Aldrich, USA) and 20% FCS. Cells 
were frozen in cryovials and stored in liquid nitrogen tank until further use. 
3.1.2 Isolation of mouse alveolar type II cells 
Alveolar epithelial cells were isolated as described previously with some modifications85. 
Briefly, mice were anaesthetized and lungs were perfused with 1xPBS then filled with 
approximately 1.5ml sterile dispase (BD Biosciences, Germany) and 0.5ml low-melting 
agarose (Sigma-Aldrich) via the trachea. After gelling, lungs were removed and incubated 
further in dispase for 40 minutes at room temperature with rotation. The trachea and 
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surrounding connective tissue were removed and lung tissue was minced in DMEM/2.5% 
HEPES with 0.01% DNase (50 μg/ml; Sigma) and incubated with shaking for further 10 
minutes at 37⁰C. Digested tissue was washed with PBS and single cells were separated by 
successive filtration through 100-µm and 40-μm nylon filters and collected by 
centrifugation86, 87. To remove the immune cells, single cell suspension was incubated with 
CD32 (3μl/lung) and CD45 (7μl/lung) antibodies for 30 minutes at 37°C. Cell-antibodies 
mixture was centrifuged, resuspended in 7 ml medium and incubated with 1xPBS-pre-
equilibrated streptavidin magnetic beads for 30 minutes on a rolling table. After purification 
of all bound cells, the supernatant containing all epithelial cells was plated on fibronectin-
coated plates. Once the cells adhered to the plates, they were washed several times with 
1xPBS to get rid of erythrocytes. The cells were kept in culture for maximum three days. 
3.1.3 Stimulation and inhibition of NF-ƙB signalling pathway 
To stimulate the classical signalling pathway of NF-ƙB, cells were treated with 
lipopolysaccharide LPS (Sigma Aldrich, Germany) at a concentration of 5µg/ml or 10µg/ml 
for 2h (or as specified) or with human recombinant tumour necrosis factor TNFα (R&D 
Systems, Minneapolis, USA, 210-TA) at a concentration of 10ng/ml for 30 min. For inhibition, 
sc-514 In-Solution (Santa Cruz, Germany) was used to selectively inhibit IKK2 at a final 
concentration 0f 12.5µM. Other inhibitors were also applied such as MG-132 (Merck 
Millipore, Darmstadt, Germany) at a concentration of 25µM, Bay 11-7085 (Cayman Chemical 
company, Estonia) at 10µM and parthenolide at 20µM (Cayman Chemicals).   
3.1.4 Transient cell transfection 
Cells were seeded in 6-well plates at a density of 3x105cells/well and cultured overnight 
to attach. When they reached 70-80% confluency, they were transfected with the desired 
plasmid using TurboFectTM Transfection reagent (Thermo Fisher Scientific Inc., Germany) or 
Lipofectamine® 2000 (Life Technologies, Germany) for more resistant cells at a ratio of 2:1 or 
3:1, respectively (amount of plasmid DNA in µg: volume of transfection reagent in µl). 
Transfection efficiency was checked after 24 hours and ranged from 70% -90% according to 
the cell line. Cells were collected 24h post-transfection for RNA isolation; and for protein 
isolation and functional assays 48h post-transfection.  
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3.1.5 Stable cell lines generation 
Stable cells were generated via lentiviral transfection. First HEK293T cells were cultured 
until 80% confluent and then transfected with the lentiviral vector of interest together with 
viral packaging vector psPAX2 and envelope vector pMD2G at a ratio of 3:2:1 using 
TurboFect transfection reagent (Thermo Fisher Scientific Inc., Germany) and serum-free 
medium. Three lentiviral vectors were used: empty vector pCDH-CMV-MCS-EF1-copGFP-
T2A-Puro depicted in Fig.3.1a (SBI System Biosciences, USA), IKK2-S177E-S181E, a gift from 
Anjana Rao (Addgene plasmid #11105)88, cloned into the pCDH empty vector and referred to 
as IKK2CA (Fig. 3.1b).  
 
 
Figure  3.1 Vector map of lentiviral vectors. a) pCDH-CMV-MCS-EF1-copGFP-T2A-Puro empty vector; b) pCDH--
CMV-IKK2CA-EF1-copGFP-T2A-Puro which carries two activation mutations at S117 and S181 making IKK2 
constitutively active. (Adpated and modified from SBI System Biosciences pCDH cloning and expression 
lentiviral vectors). 
 
After 48h of transfection, cell medium containing the viral particles was collected, 
centrifuged to get rid of cell debris and then supernatant was filtered through 0.45µm-
nitrocellulose filter. Viral particles were used immediately or were stored in aliquots at -80°C 
until further use. To transduce target cells with the lentiviral vector of interest, they were 
seeded in 24-well plate and cultured until 70-80% confluency. The corresponding viral 
particles were mixed with polybrene (Fermentas, Germany) at final concentration of 
0.8µg/ml with fresh medium, incubated at room temperature for 5min and then pipetted on 
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top of the cells. Two days later, the transduction efficiency was estimated and positive cells 
were selected with puromycin at a concentration 6-8µg/ml according to the cell line. 
LLC1 cells were transduced by spinoculation or spin infection. A volume of 1-2ml viral 
particles was added to 50 000 cells in a 50ml-Falcon tube to which 2µl polybrene (stock is 
10mg/ml) was added. The mixture was mixed well and incubated at room temperature for 5 
minutes. The cells-viral particles mixture was then centrifuged at 2500rpm at 30°C for 3h, 
after which the supernatant was removed. Cells were resuspended in medium 
supplemented with 10% FCS and plated in 24-well plate. After 48h, cell selection was started 
by the addition of puromycin.   
3.1.6 Immunocytochemistry (ICC) 
Cells were seeded in 8-well chamber slides (BD BioSciences, Germany) at a density of 
0.5-1x104 cells/ml. When confluent, the supernatant was removed and cells were washed 
with 1xPBS for 5 min. Then cells were fixed either with ice-cold acetone/methanol mixture 
(1:1) at -20°C for 30 min or with 4% PFA at room temperature for 30 min. After fixation cells 
were washed 3 times with 1x PBS and blocked with 5% BSA/0.1% triton X for 1h at room 
temperature. Primary antibodies (p50, RelA/p65 from Santa Cruz, Germany and SP-C from 
Millipore, Germany) were prepared at a dilution of 1:200 in the blocking solution and added 
to the cells overnight. After incubation, cells were washed 4 times with 1xPBS and incubated 
with the fluorescently conjugated secondary antibodies (anti rabbit IgG- AlexaFluor®488, 
AlexaFluor®555 and AlexaFluor®594, Invitrogen, Germany) at a dilution of 1:1000 for 1h 
protected away from the light. Cells were washed 4 times with 1xPBS and nuclei were 
counterstained with 4', 6-diamidino-2-phenylindole (DAPI, Life Technologies, USA) diluted 
1:100 for 10 min.  After a final wash with 1xPBS cells slides were mounted with Dako 
fluorescent mounting medium (Dako North America, Inc., USA) and examined under Leica 
fluorescent microscope. (Details on antibodies listed in Appendix I, Table 9.2 for primary 
antibodies and Table 9.4 for secondary antibodies). 
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3.1.7 Proximity ligation assay (PLA) 
A549 cells were grown in 8-well tissue culture chamber slides (Sarstedt, Germany) and 
transfected with pIKK2CA, pMTA2 or shMTA2. Proximity ligation assay was performed using 
the Duolink® In Situ fluorescence red starter kit mouse/rabbit (OLink Bioscience, Uppsala, 
Sweden) according to manufacturer’s protocol.  Briefly, cells were fixed in ice-cold 
acetone/methanol mix for 20min at -20°C and permeabilized with 1xPBS  containing 01% 
TritonX-100 for 10minutes. Duolink In Situ blocking solution was added to the chamber 
slides and incubated in a humidity chamber for 30min at 37°C. Primary antibodies, MTA2 
(Abcam, Germay) and p-p65 (Santa Cruz, Germany), were diluted 1:200 in the provided 
antibody diluent solution and incubated overnight with the cells. After incubation primary 
antibodies were removed and slides were washed in 1x Wash Buffer A twice each for 5min. 
PLA probes were diluted 1:5 and added to samples to incubate in a pre-heated humidity 
chamber for 1h at 37°C. PLA probes were then discarded, slides washed in 1xWash Buffer A 
twice for 5min each and Ligation-Ligase solution was added. After incubation for 30min at 
37°C, solution was removed and slides were washed twice in 1xWash Buffer A under mild 
agitation. The amplification-polymerase solution was prepared under light protection and 
incubated on the samples for 100min at 37°C. Finally, cells were washed twice in Wash 
Buffer B for 10min each, then once in 0.01x Wash Buffer B for 1min. After drying, slides were 
mounted Duolink In Situ Mounting Medium with DAPI and nail polish was used to seal the 
edges. Microscopic analysis followed using the Leica fluorescent microscope.  
 
3.2 Functional assays for cells 
3.2.1 Cell proliferation by BrdU incorporation 
Proliferation of cells was determined using colorimetric cell proliferation ELISA BrDU kit 
(Roche, Germany) according to the manufacturer’s protocol. Cells were seeded as 6-8 replica 
in 96-well plate at a density of 1x104 cells/well in 100µl of full medium and cultured 
overnight. Medium was then removed and cells washed with 1xPBS before they were serum 
starved in medium without serum supplementation.  After 24h of serum starvation, the 
medium was replaced with medium to be tested and incubated for as long as required for 
the stimulation or inhibition. BrdU was then added to the cells for 2-4h in serum-free 
medium. Cells were then fixed and BrdU incorporated in proliferating cells was detected 
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with antibody having horse radish peroxidase (HRP) conjugation. An HRP-substrate was 
added and the colour developed was measured spectrophotometrically at 370nm with 
reference measurement at 492nm using Tecan Infinite M200 PRO reader (Tecan Group Ltd, 
Switzerland). Proliferation of cells was plotted as function of absorbance at 370nm. 
3.2.2 Boyden chamber migration assay 
For the evaluation of the migratory capacity, the Boyden chamber migration assay89 was 
performed. In 24-well companion plates (BD BioSciences, Franklin Lake, USA), a volume of 
700µl of media complemented with 10% FCS was distributed into the wells. Cells were 
seeded on filters (8.0μm pore size; BD Falcon cell culture insert, transparent PET membrane, 
Corning, Inc.) at a density of 5×104 cells per filter in 300μl serum-free medium. Cells were 
incubated for 6-8 hours in the incubator at 37°C with 5% CO2. After incubation the filters 
were washed with 1×PBS and dried from the inner side with a cotton swab to remove cells 
that haven’t migrated. For fixation, filters were submersed in methanol (Roth, Germany) for 
3 minutes, and stained for 10 minutes with Crystal Violet solution (Sigma-Aldrich, USA) 
diluted 1:10 with ddH2O. After the final wash in ddH2O, filters were dried, cut out from the 
inserts and mounted on slides with Pertex (Medite GmbH, Germany). Slides were scanned 
with Nanozoomer 2.0HT digital slide scanner C9600 (Hamamatsu Photonics, Japan) and the 
migrated cells per membrane were counted using ImageJ software. 
3.2.3 Soft agar attachment-independent colony formation assay 
Soft agar assay was performed to characterise LLC1 tumour cells for their ability to grow 
independently of anchorage.  LLC1 control cells as well as LLC1 transfected with empty 
vector, IKK2CA or shMTA2 were compared. For this assay, 0.7% bottom agar was prepared by 
mixing 2x DMEM with sterile agar stock solution (1.8%). After plating in 6-well plates, agar 
was left to solidify for at least one hour. Cells were trypsinized and cell samples were 
prepared in 0.3% top agar at a concentration of 5x104cells/ml at 42°C. Plate was left to cool 
down before incubating at 37°C with 5% CO2. Colony formation was monitored regularly 
after one week under the microscope and after 14 days of culture, images were taken with 
representative colonies. Images were analysed by ImageJ software for counting the number 
of colonies and measuring their area. 
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3.3 Molecular biology & biochemical methods 
3.3.1 RNA isolation 
For isolation of RNA from tissues, 50-100mg tissue were homogenised in 1ml Trizol 
(Qiagen, Germany) twice at 6500rpm for 25 seconds using Precellys® Ceramic Kit 1.4 
(PEQLAB, Erlangen, Germany) and Precellys homogeniser. For RNA isolation from cells, they 
were first washed with PBS then were directly scraped in Trizol (1m/10cm plate). Cells or 
homogenized tissue were centrifuged at 12000rpm for 30min at 4°C and RNA was isolated 
according to manufacturer’s protocol. In brief, chloroform (Sigma Aldrich, Germany) was 
added to the supernatant (0.2ml for each ml Trizol), mixed vigorously, incubated for 10min 
at room temperature and centrifuged at 12000rpm for 15min at 4°C. The upper aqueous 
layer was transferred to another tube and overlayed with 500µl isopropanol/ml Trizol. After 
gentle mixing, mixture was incubated for 10min at room temperature. To collect the 
precipitated RNA, mixture was centrifuged at 12000 rpm for 10 min at 4°C. The supernatant 
was then removed and the pellet was washed twice with 75% ethanol and then left to dry. 
The isolated RNA was then resuspended in an appropriate amount of DEPC-treated water 
and the concentration and purity of RNA were measured using NanoDrop (Peqlab 
Biotechnologies GmbH, Erlangen, Germany). After checking the integrity of RNA on 1% 
agarose gels, RNA was stored at -80°C until further use. 
3.3.2 Reverse transcription for cDNA synthesis 
To ensure for better purity, RNA was pre-treated by DNase (Fermentas, Germany) to 
eliminate possible contamination with genomic DNA. The RNA concentration was adjusted 
to 100ng/µl and 800ng of RNA in total were used per sample. The DNase treatment was 
performed using a master mix as described in Table 3.1 and incubated for 30min at 37°C. To 
stop the enzymatic action of DNase, 1µl of EDTA was added to each sample and incubated 
for further 10min at 65°C.  
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Table  3.1 DNase Treatment of RNA 
 
RNA was then transcribed to cDNA with Oligo-dT primers using ImProm-II™ Reverse 
Transcription System (Promega, Madison, USA) according to the suppliers’ recommendation. 
A volume of 8µl RNA (100ng/µl) were mixed with 2µl oligomers and incubated for 6min at 
70°C. After cooling, 30µl of the master mix described in Table 3.2 were added and incubated 
in the thermocycler. The High Capacity cDNA Reverse Transcription Kits (Applied Biosystems, 
USA) was also applied for cDNA synthesis. The synthesized cDNA was diluted 1:3 before 
proceeding with qPCR. 
Table  3.2 Master mix for cDNA synthesis using ImProm-IITM Reverse Transcription System 
 
 
 
 
 
 
 
 
3.3.3 Quantitative real time polymerase chain reaction (qRT PCR) 
The Real Time-qPCR reaction mixture was prepared using iQTM SYBR Green Supermix 
(Bio-Rad, Germany) according to manufacturer’s recommendations (Table 3.3). Exon 
spanning primers were designed to produce an amplicon size varying from 100-200bp. 
Component Volume (µl) Incubation Conditions 
DNase Buffer 1 
30 min at 37°C RNase Inhibitor 0.33 
DNase 1 
EDTA 1 10 min at 65°C 
Component 
Final 
Concentration 
Volume (µl) 
ImProm-IITM 5x reaction buffer 1x 8 
MgCl2 (25mM) 5mM 4 
dNTP Mix (10mM) 0.5m 2 
RNasin® ribonuclease inhibitor 0.5U 1 
ImProm-IITM reverse transcriptase (RT) 1U 2 
Nuclease free water   13 
Total  30 
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Appendix II, Table 9.5 and Table 9.6 list all primers used, their sequence and the 
corresponding annealing temperature.  
Table  3.3 Reaction mixture for qPCR 
 
 
 
 
 
 
Master mixture and cDNA template were pipetted into non-skirted 96-well plates and 
the reaction was run in Mx3000P qPCR system using the reaction conditions described in 
Table 3.4.  Data were analysed with the MxPro2000 software and the level of mRNA 
expression was represented as ΔCt values (Ct value of the housekeeping gene – Ct value of 
the gene of interest). The data were normalized to the expression of HPRT (hypoxanthine 
phosphoribosyltransferase1) as housekeeping gene. 
Table  3.4 Reaction conditions for qPCR programme 
 
 
 
Component Volume (µl) 
iQTM SYBR® Green Supermix (2x) 10 
Forward primer (10mM) 0.5 
Reverse primer (10mM) 0.5 
Nuclease free water 7 
cDNA template 2 
Total 20 
Temperature Time Number of Cycles 
95°C 3 min 1 
95°C 15 sec 
40 
58°C or 60°C 20 sec 
95°C 1 min 1 
55°C 30 sec 1 
95°C 30sec 1 
Materials & Methods 
30 
 
3.3.4 Protein isolation 
Tissue was homogenised as for RNA with Precellys ceramic kit. Cells or tissue were 
ruptured using RIPA buffer (Chem Cruz, Santa Cruz Biotechnology, Inc) supplemented with 
protease inhibitor (Santa Cruz, Germany) and phosphatase inhibitors (PMSF as 1mM final 
concentration and sodium orthovanadate as 0.2mM final concentration). For 100mg tissue 
500µl RIPA buffer was used; for cells 150µl RIPA buffer was used for 10cm-plate and 70µl 
RIPA buffer for one well of a 6-well plate. Cell suspension or homogenized tissue were 
incubated for 10 minutes at 4°C then centrifuged at 12000rpm for 30min at 4°C. The 
supernatant was collected and stored at -80°C until further use.  
For isolation of cytoplasmic and nuclear protein fractions, NE-PER™ Nuclear and 
Cytoplasmic Extraction Kit (Thermo Scientific™, Germany) was used following the 
manufacturer’s instruction. Both fractions were collected and stored at -80°C until further 
use.  
The protein content was quantified by a modified Lowry assay using DCTM Protein Assay 
(Bio-Rad, Munich, Germany). Different concentrations of bovine serum albumin (BSA, 
BioRad, USA) were used as a protein standard ranging from 0.125-2µg/µl. Samples from 
tissues were diluted 1:10 and those from cells were diluted 1:5 to be in the range of the 
standard. The developed blue colour was measured at 750nm using Tecan Infinite M200 
PRO microplate reader (Tecan Group Ltd, Switzerland). 
3.3.5 Co-Immunoprecipitation (Co-IP) 
Protein was isolated as described above section 2.2.3 and 500µg protein were diluted to 
1µg/µl protein in Co-IP buffer (or modified cell lysis buffer) and incubated with 1µg antibody 
or IgG control for 3h or overnight at 4°C with rotation. After equilibration of protein A-
agarose beads (GE Healthcare, Germany) in modified cell lysis buffer, 30µl beads were added 
to each protein/antibody sample. Samples were incubated with the beads for 3h at 4°C. The 
protein fraction pulled down by the antibody and beads were collected by centrifugation at 
14000rpm for 10min at 4°C. The supernatant was collected to check for unbound proteins 
and the protein pellet was washed twice with RIPA buffer, twice with Co-IP buffer and once 
with 1xPBS. Finally the pellet was resuspended in approximately 50µl of 2xSDS sample 
application buffer and prepared for western blotting. As control, 10% input was used as 
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positive control and IgG control of the respective species was used as negative control 
(Buffers used are listed in Appendix III, Table 9.10). 
3.3.6 Western blotting 
Protein samples were mixed with 5x SDS sample application buffer and boiled for 3-5min 
and then loaded on 10% SDS PAGE gels. After the run, gels were electrophoretically 
transferred to nitrocellulose membranes and blocked in either 5% non-fat milk in TBS(T) or 
in 5% BSA in TBS(T) for 1h at room temperature with agitation. After incubation with the 
primary antibody overnight at 4°C, membranes were washed three times in TBS(T) and then 
incubated with the corresponding secondary HRP-coupled antibody for 1h. The SuperSignal™ 
West Femto Chemiluminescent Substrate (Thermo Fisher Scientific, Inc., Germany) was 
added after washing the membranes and development was done using ImageQuant™ LAS 
4000 Version 1.2 (GE healthcare Life Sciences, Germany). (Antibodies used and the 
corresponding conditions are listed in Appendix I, Table 9.1. Buffers used are listed in 
Appendix III, Table 9.11). 
3.3.7 Chromatin Immunoprecipitation 
Cells were seeded in 10cm plates, treated and cultured until confluency. Formaldehyde 
was added to a final concentration of 1% for 10min at room temperature to crosslink protein 
and DNA. Glycine was then added at a final concentration of 125mM for 5min to quench 
formaldehyde. All further steps were carried out on ice. Crosslinked cells were washed three 
times with cold 1xPBS and collected by scraping. To lyse the cells, they were incubated with 
cold L1 lysis buffer supplemented with protease and phosphatase inhibitors and 2mM DTT 
for 5min. Lysed cells were centrifuged at 3000rp for 5min to separate the supernatant with 
the cytoplasmic fraction and the chromatin in the pellet.  Cell nuclei were then resuspended 
with L2 nuclear resuspension buffer supplemented with protease and phosphatase inhibitors 
and 2mM DTT.  
The chromatin was then sonicated using Bioruptor® Next gen (Diagenode, Belgium) for 
16 cycles for A549 cells at 90% power. After centrifugation at maximum speed for 10min, the 
supernatant containing the chromatin solution was collected, diluted with DB-dilution buffer 
supplemented with protease and phosphatase inhibitors and then incubated with 80µl 
protein A or G agarose beads conjugated with salmon sperm DNA for 1h at 4°C with rotation. 
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The supernatant DNA-protein precleared sample was collected after centrifugation at 
1000xg for 3min and distributed into equal amounts to be incubated overnight at 4°C with 
2µg of antibody or IgG in a final volume of 1.8ml. From the DNA-protein sample 10-20% 
were stored as input control. After incubation with the antibodies of interest, 30µl agarose 
beads were added and incubation was continued for further 2h. Supernatant was removed 
by centrifugation and kept to check for proper binding and the remaining agarose beads 
with bound DNA-protein moiety were washed with 800µl of low salt washing buffer, then 
high salt washing buffer, then LiCl washing buffer and finally twice with TE buffer (Buffers 
used are listed in Appendix III, Table 9.9). 
To de-crosslink and elute the DNA, 100µl of freshly prepared DNA elution buffer was 
added to the beads together with 0.5µl RNase A (1mg/ml, Fermentas, Germany) and 
incubated at 37°C on thermo-shaker (900rpm) for 2h. To digest the protein 5µl of 10mg/ml 
proteinase K (Sigma Aldrich, Germany) was added to the beads and incubated at 56°C for 2h 
with shaking. Finally NaCl was added to a final concentration of 0.2M and incubated 
overnight at 65°C. Samples were then centrifuged for 1min and the supernatant collected 
and the DNA content in it was purified with QIAquick PCR purification kit (Qiagen, Germany) 
according to the manufacturer’s instruction. Finally, DNA was diluted 1:4 with water and 
used for qPCR. (Primers used for ChIP assay and their sequences are listed in Appendix II, 
Table 9.8).    
3.3.8 Fractionation of nuclear lysate by sucrose gradient 
H1650 cells were cultured in 15cm-culture plates, two for each condition. After 
treatment with LPS and TNFα for 6h, cells were washed twice with 1xPBS. Cells were 
collected by scraping and subsequent centrifugation. Using 2ml of hypotonic lysis buffer 
complemented with protease and phosphatase inhibitors, cell pellets were lysed by 
vortexing and incubation on ice for 10-15min followed by centrifugation. The pellet which is 
the nuclear fractions was lysed by 450µl native nuclear lysis buffer.  
 A sucrose gradient was prepared by mixing 1ml of 5%, 13.75%, 22.5%, 31.25% and 44% 
of sucrose. Tubes were incubated overnight at 4°C to form a continuous gradient. Carefully 
the nuclear samples were overlayed on top of the sucrose gradient and centrifuged at 
375000rpm for 16h30min. After centrifugation, the plastic tubes were gently pierced from 
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the bottom to collect 500µl fractions. The proteins collected were then examined by 
immunoblotting (Buffers used are listed in Appendix III, Table 9.10). 
3.3.9 Cloning of pCDH-IKK2CA 
The plasmid containing IKK-2 S177E S181E (short pIKK2CA) was a gift from Anjana Rao 
(Addgene plasmid #11105)88. Using PCR cloning, XbaI and BamH1 restriction sites were 
introduced to the amplified IKK2CA sequence. Both the empty lentiviral vector pCDH-CMV-
MCS-EF1-copGFP-T2A-Puro (short pCDH) (Fig. 3.1) and the modified purified IKK2CA 
sequence were digested with XbaI and BamH1 restriction enzymes to have matching 
cohesive ends.  The digested fractions were run on 1% agarose gel and the correct bands 
(2300bp for IKK2CA and 7544bp for pCDH) were excised and purified from the gel using Gene 
EluteTM gel extraction kit (Sigma Aldrich, Germany).  Both vector and insert were mixed at a 
ratio of 1:3 and ligated overnight at 16°C using T4 DNA ligase (New England Biolabs, 
Germany).  
The ligation product was checked on agarose gel and used to transform DH5α E. coli 
competent cells (New England Biolabs, Germany). Transformed bacteria were cultured on 
ampicillin plates (100µg/ml) for selection. Selected colonies were cultured in 3ml LB broth 
containing ampicillin and the plasmids were purified using Plasmid Mini Kit (Qiagen, 
Germany) or peqGold Plamsid Miniprep (Peqlab). Plasmids were screened by double 
restriction digestion, by qualitative PCR followed by agarose gel electrophoresis, and by 
sequencing. The clone with the correct plasmid was cultured overnight in maxi LB cultures 
supplemented by ampicillin at 37°C. Plasmid was then purified using NucleoBond Extra Maxi 
kit (Machery-Nagel GmbH, Germany).  
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3.4 Activity assays 
3.4.1 NF-Gluciferase reporter assay 
Cells were seeded in 48-well plates and cultured until they reached 70-80% confluency. 
Then they were transfected with NF-Gluc plasmid, a kind gift from Dr. Bakhos A. Tannous90. 
This plasmid has a reporter system expressing the secreted Gaussia luciferase (Gluc) under 
NF-ƙB responsive promoter elements. After 24h or 48h, 50µl of the cell-free conditioned 
medium was collected and activity was assayed by adding equal volume of 20µM of 
stabilized colenterazine substrate (p.j.k. GmbH, Germany) and measuring photon count 
using Infinite® 200 PRO microplate reader (Tecan, Switzerland).  
3.4.2 NF-ƙB activity assay 
NF-kB p65 transcription Factor assay kit (ab133112, Abcam, Germany) was used to 
measure NF-ƙB activity in the isolated nuclear extracts. This ELISA-based assay measures the 
binding of p65 present in the nuclear samples to NF-ƙB-specific double stranded DNA 
sequence containing NF-ƙB response elements immobilized on the ELISA plate. Nuclear 
extracts were added to the ELISA plate and incubated overnight.  The plate was washed and 
incubated with antibody against p65. After incubation with the HRP-conjugated secondary 
antibody, substrate was added and absorbance was measured at 450nm using Infinite® 200 
PRO microplate reader (Tecan, Switzerland).   
3.4.3 HDACs activity assay 
EpigenaseTM HDAC activity/inhibition direct colorimetric assay kit (Epigentek, USA) was 
used to determine HDAC activity in nuclear extracts of cells or in whole cell lysate.  An 
amount of 10µg protein was added per well, which are coated with acetylated histone HDAC 
substrate. The deacetylated products were detected with a specific antibody conjugated 
with HRP and measured spectrophotometrically at 450nm. 
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3.5 Histological techniques 
3.5.1 Haematoxylin & Eosin staining (H&E staining) 
Paraffin sections were cut with 0.3µm thickness and were stained with haematoxylin 
and eosin (H&E) using standard protocols. Briefly, sections were deparaffinised and hydrated 
by heating at 60°C for 1h and then by passing the slide through a series of three times of 
xylol, followed by a decreasing concentration of ethanol from 99,6% till 70%. After washing 
shortly in water, sections were incubated in Mayer’s hematoxylin (AppliChem, Darmstadt, 
Germany) for 20min, washed shortly under running water to get rid of excess dye and then 
incubated with Eosin Y (AppliChem, Darmstadt, Germany). Slides were then washed briefly 
in water then rehydrated in a series of increasing ethanol concentration and then 3 times in 
xylol each for 10min. Finally slides were mounted with Pertex (Medite GmbH, Germany) and 
sections were scanned with Nanozoomer 2.0HT digital slide scanner C9600. 
3.5.2 Immunohistochemistry (IHC) 
Mouse lungs were dissected and fixed with 4% paraformaldehyde in 1xPBS overnight at 
4°C. The tissue samples were rinsed in 1xPBS, dehydrated, and then embedded in paraffin 
blocks. Three-micrometer tissue sections were deparaffinized, rehydrated in graded series of 
alcohol. For antigen retrieval, sections were cooked in 10mM citrate buffer for 20 minutes, 
then kept warm for further 10min or they were treated with Trypsin or EDTA according to 
the antibody. Endogenous peroxidase activity was quenched with methanol containing 3% 
H2O2. Non-specific binding was blocked with 5% of specific serum or 10% BSA for 1 hour. 
After blocking, sections were incubated with primary antibodies overnight at 4°C. 
Immunohistochemistry was performed using the following antibodies at the indicated 
dilutions: CD11b (1:100), CD3 (1:200) and MTA2 (1:200). Following primary antibody 
incubation, sections were incubated with the corresponding secondary antibodies of the 
ImmPRESS peroxidase reagent kit (Vector Laboratories, USA) for 60 minutes at room 
temperature then sections were developed with DAB or NovaRed (Vector Laboratories). 
Sections were then counterstained with hematoxylin solution, Gill Nr.1 (Sigma Aldrich, USA) 
or methylgreen (Vector Laboratories Inc, Burlingame, USA) and mounted with Pertex after 
dehydration. Finally, slides were scanned with Nanozoomer 2.0HT digital slide scanner 
C9600 (Hamamatsu Photonics, Japan). Negative controls included the omission of the 
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primary antibody. (Detailed information on the primary antibodies used is listed in Appendix 
I, Table 9.9). 
3.5.3 Immunofluorescence 
For immunofluorescence, tissue sections were hydrated and incubated with trypsin for 
10 min for antigen retrieval or with citrate for 30min. Then, tissues were blocked in 5% BSA 
with 0.1% Triton-X in PBS for 1h at RT, to avoid unspecific binding of the antibodies. The 
following primary antibodies were used:  p-p65 (Ser311), p65, MMP9, C-Raf, PCNA, MTA2  
and IKK2 all diluted 1:200. After incubation with the primary antibodies at 4°C overnight, 
slides were incubated with the corresponding Alexa Fluor®-labelled secondary antibodies 
(Invitrogen, Molecular Probes, Invitrogen, Paisley, UK) at a dilution of 1:1000, counterstained 
with 4,6-diamidino-2-phenylindole (DAPI, Life Technologies, USA) and mounted with Dako 
fluorescent mounting media (Dako, North America, Inc., USA). Quantification of total 
fluorescent intensity was carried out by computer-aided image analysis using ImageJ 
software. (Detailed information on the primary antibodies used and the corresponding 
conditions is listed in Appendix I, Table 9.9). 
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3.6 Animal experiments 
Wildtype C57Bl/6J animals were purchased from Charles River Laboratories (Sulzfeld, 
Germany) and transgenic animals were provided by Prof. Ulf Rapp. Animals were kept in 
individually ventilated cages (IVC) in a pathogen-free environment and were handled in 
accordance with the European Union commission on Laboratory animals. Animal study 
proposals were approved by the Regierungspräsidium Giessen, the local regulatory 
authorities for animal research in Hessen, Germany (Animal proposals B2/233 and B2/1026).  
3.6.1 Transgenic animal model 
SpC C-Raf BxB 
SpC C-Raf BxB transgenic mice were maintained as hemizygotes in the C57 BL/6 mouse 
strain background. They express a truncated C-Raf -lacking the regulatory domain- under the 
control of the surfactant protein C (SPC) promoter. This leads to lung-targeted expression of 
C-Raf BxB in alveolar type II cells leading to the formation of lung adenomas as early as 3 
months of age18. Polymerase chain reaction was used to secure the transgenic status as 
described in section 3.6.3.  
Tet-O-IKK2CA and Tet-O-IKK2DN  
Mice were developed by Wirth T group (Ulm University, Germany). The mice carry either 
a constitutively active form of IKK2 with activating mutations at S177E and S181E (referred 
to as Tet-O-IKK2CA or short IKK2CA), or they carry a down-regulated form of IKK2 with 
mutation at D145N (referred to as Tet-O-IKK2DN or short IKK2DN)91. As such the mice don’t 
show any phenotype. 
3.6.2 Breeding and Induction 
Tet-O-IKK2CA and Tet-O-IKK2DN were cross bred with SpC rtTA mice to obtain ATII-specific 
IKK2 changes, referred to as SpC rtTA/Tet-O-IKK2CA (short SPC/IKK2CA) or SpC rtTA/Tet-O-
IKK2DN (short SPC/IKK2DN), respectively. The double transgenic mice were induced by 
doxycycline (Fagron, USA) supplemented in food (725mg/kg). Transgene induction started at 
week 5 postnatal after complete lung development. 
For the generation of compound triple transgenic mice, SpC C-Raf BxB mice (referred to 
as BxB) were cross bred with SpC rtTA/Tet-O-IKK2CA or SpC rtTA/Tet-O-IKK2DN to generate 
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SpC rtTA/Tet-O-IKK2CA/SpC C-Raf BxB (short: SPC/IKK2CA/BXB) and SpC rtTA/Tet-O-
IKK2DN/SpC C-Raf BxB (short: SPC/IKK2DN/BXB), respectively. Transgenes were expressed 
conditionally in ATII cells upon feeding the mice with food supplemented by doxycycline. 
Induction of compound mice was for 50-56 weeks.  
3.6.3 Genotyping  
Mice were genotyped via tail tip samples of pups. Tails were lysed in 190µl of tail lysis 
buffer (50mM EDTA pH8, 50 mM Tris pH 8, 0.5% SDS) supplemented with 10µl proteinase K 
(10mg/ml; Sigma Aldrich, Germany) and incubated at 56°C for 4h or overnight. After 
incubation and complete lysis of tail tissue, the samples were centrifuged for 15 minutes at 
maximum speed at 4°C. Then samples were diluted 1:10 before using as a DNA template for 
PCR using the master mix described in Table 3.5. Primers used for genotyping are listed in 
Appendix II, Table 9.7. 
Table  3.5 Reaction master mix for genotyping PCR 
 
 
 
 
 
 
  
 
3.6.4 Subcutaneous xenograft (autochthonous) model 
Mice were injected subcutaneously with 3x106 cells in 0.2ml PBS into their hind flank. 
Tumours were measured every 4 days using an external digital caliper to measure the 
greatest longitudinal diameter (length) and the greatest transverse diameter (width). The 
tumour volume was calculated by the modified ellipsoidal formula92. 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑉𝑉𝑇𝑇𝑉𝑉𝑇𝑇𝑇𝑇𝑉𝑉 (𝑇𝑇𝑇𝑇3)  = 12 (𝐿𝐿𝑉𝑉𝐿𝐿𝐿𝐿𝐿𝐿ℎ 𝑥𝑥 𝑊𝑊𝑊𝑊𝑊𝑊𝐿𝐿ℎ2) 
Component Volume (µl) 
Taq buffer 10x 3 
dNTP (10mM) 3 
Forward primer (10mM) 0.3 
Reverse primer (10mM) 0.3 
Taq Polymerase 0.3 
Nuclease free water 21.1 
cDNA template 2 
Total 30 
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The whole body weight of the mice was also monitored every 4 days throughout the 
experiment. Mice were sacrificed after 21 days and lungs and subcutaneous tumours were 
isolated to quantify expression on both protein and RNA level.  
3.6.5 Magnetic resonance imaging of the lung 
Mice were anaesthetized with 1.5% isofluorane and placed abdominally inside the coil of 
a magnetic field.  The abdominal area of mice was scanned using respiratory-gated UTE-3D 
sequence with a repetition time of 8.0ms, echo time of 20µs, slice thickness/interslice 
distance: 0.39/0.39mm, field of view 2.50x2.70x5.00cm3 and a matrix of 128/128/128. 
Images were analysed in axial view using ImageJ software. The heart ventricles in the upper 
part of the images were used to normalize each image93.  
3.6.6 Lung compliance 
Lung compliance was measured by FlexiVent (SCIREQ, emka Technologies, France) which 
is a computer-controlled research ventilator for small animals. After anesthetization, mice 
were connected to FlexiVent via the trachea and ventilated with a tidal volume of 10ml/kg at 
a frequency of 150breaths/min and a positive end-expiratory pressure of 3cm H2O. Three 
perturbations were performed in the following order: deep inflation v7.0; an 8s broadband 
perturbation (primewave-8); pressure-volume loops including stepwise inflation and 
deflation of 1ml of air (PVs-V). The three perturbations were performed and recorded. The 
inspiratory capacity (IC) was obtained through the perturbation of deep inflation v7.0. A 
forced oscillation perturbation, primewave-8, was applied to calculate the resulting 
impedance data as tissue damping or tissue resistance (G), tissue elastance (H) and tissue 
hysteresivity (G/H = η). PV-loops were generated to obtain static compliance (Cst)94. After 
finishing the measurements mice were then used for further analysis and tissue collection.  
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3.7 Statistical analysis 
Statistical analyses were performed with GraphPad Prism 5 Software (GraphPad 
Software, Inc.). Student's t test (two-tailed) was used to compare two groups. When more 
than two groups were compared, differences among the groups were determined by one-
way ANOVA with Tukey’s posttest for unpaired non-parametric variables. Outliers were 
identified using ROUT with Q=1%. Data are expressed mean ± SEM; statistical significance 
was set at p ≤ 0.05. Significance level is noted as follows: * p ≤ 0.05, ** p ≤ 0.01, ***p≤0.001, 
****p ≤ 0.0001. 
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4 Results 
4.1 NF-ƙB is increased in cancer cells  
NF-ƙB is a major inflammatory pathway that is activated both via intrinsic and extrinsic 
factors50. In order to check for the NF-ƙB pathway in lung cancer, several lung cancer cell 
lines (A549, Colo699, H1650, and H2122) were analysed for their basal expression of p50 and 
p65 (referred to as NFKB1 and RELA, respectively). By comparing them with BEAS-2B (B2B) 
cells as control cells, which are normal but immortalized human bronchial epithelial cells, 
A549, Colo699, H1650 cell lines showed increased levels of both NF-ƙB genes whereas 
H2122 showed only higher expression of NFkB1 (Fig. 4.1a). However, after LPS (5 µg/ml) 
stimulation for 2h, all cell lines showed higher level of activation as measured with target 
genes MMP9 and FN1 (Fig 4.1b). NFKB1 and RELA are also target genes for NF-ƙB canonical 
signalling which are responsible for positive feedback activation sustaining the activity of NF-
ƙB. The extent of activation varied between cell lines depending on the target gene selected 
and on the exposure time to stimulus.  
In the canonical NF-ƙB pathway, LPS and TNFα are both classical external stimulants of 
NF-ƙB. Cells were transfected with NF-Gluc vector, a reporter plasmid expressing Gaussia 
luciferase under the response elements of NF-ƙB then 24h later they were treated with 
stimulants for 24h. The activity was checked in the medium as Gaussia luciferase is secreted 
(Fig. 4.2a). Increased luciferase activity was observed upon stimulation in all cell lines (BEAS-
2B, A549, Colo699, H1650 und H2122) where TNFα showed stronger effects than LPS except 
in H2122 cell line. Another major response to stimulation is the nuclear translocation of the 
heterodimer p50/p65. Immunocytochemistry of H2122 stimulated with LPS (for 1h and 6h) 
and TNFα (for 30 minutes and 6h) showed stronger nuclear p50 and p65 after stimulation 
compared to the unstimulated control (Fig. 4.2b).  
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Figure  4.1 Activation of classical NF-ƙB pathway in different human cancer cell lines. a) Basal expression of 
NFKB1 and RELA in adenocarcinoma cell lines compared to BEAS-2B (B2B) cells as healthy control. b) Cells were 
stimulated with LPS (5μg/ml) for 2h. The level of mRNA expression of NF-ƙB and target genes fibronectin (FN1) 
and MMP9 was calculated as ΔCt of the gene of interest normalized to HPRT as housekeeping gene. Data are 
represented as mean ± SEM. * p ≤ 0.05, ***p≤ 0.001, ****p≤ 0.0001 (n=3) compared to untreated sample of 
the respective cell line. 
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Figure  4.2 NF-ƙB activity and localization upon stimulation with LPS and TNFα. a) NF-GLuciferase reporter 
assay after treatment with LPS (5μg/ml) and TNFα (5ng/ml) for 24h. Activity is represented as relative 
luminescence unit (RLU) normalized to the activity of the corresponding untreated control. Data are 
represented as mean ± SEM. * p ≤ 0.05, *** p ≤ 0.001. b) Immunocytochemistry for H2122 after LPS 
stimulation for 1h and 6h and after TNFα treatment for 30 minutes and 6h showing nuclear translocation of 
p50 (red) and p65 (green) with DAPI as nuclear counterstain. Scale bar is 25µm. Right panels show 
quantification of fluorescence intensity of individual channels of five representative images as analysed with 
ImageJ software. 
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4.1.1  NF-ƙB is classically regulated and activated via IKK2 
As NF-ƙB heterodimer consists of p50 and p65, looking for an upstream yet specific 
regulator would impact both entities but only in their active form. It is known that IKK2, a 
kinase member of the trimeric IKK-complex together with IKK1 and NEMO, regulates the 
heterodimer p50/p65 via phosphorylation of IƙB so that the inhibitor is degraded by the 
proteasome and the p50/p65 dimer is translocated to the nucleus where it drives the 
expression of various target genes95. In this respect, A549 were stably transfected with 
IKK2CA, a constitutively active form of IKK2. Overexpression of IKK2CA increased NF-ƙB activity 
as seen by NF-Gluc reporter assay (Fig. 4.3a, left panel) as well as in Western blots. At 
protein level, IKK2CA showed less IƙB and less p105, both known as NF-ƙB signalling 
inhibitors, compared to A549 with empty vector (EV). Less IƙB is a sign of the fast 
degradation of IƙB due to IKK2-dependent phosphorylation. Lower levels of p105, the 
precursor for p50, indicates its proteosomal degradation into p50 upon NF-ƙB activation. 
Besides, the level of CyclinD1, a target gene of NF-ƙB signalling, was elevated (Figure 4.3b).  
Overexpression of IKK2CA also increased both proliferation and migration of A549 cells 
(Figure 4.3c and 4.3d). In addition, cells were treated with different concentrations of a 
selective IKK2 inhibitor, sc-514, that prevents its phosphorylation and thus the downstream 
activation of p50/p65 complex. Treatment with the classical proteasome inhibitor MG-132 
was used as control for the suppression of NF-ƙB activation pathway. In line with the results 
of IKK2CA overexpression, treating the cells with either inhibitor (sc-514 or MG-132) reduced 
the luciferase activity (Figure 4.3a) as well as the functional activity of tumour cells reflected 
in decreased proliferation (Figure 4.3c, right panel) and less migratory capacity (Figure 4.3d, 
right panel). 
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Figure  4.3 IKK2 regulation of NF-ƙB activity. A549 cells were either transfected with IKK2CA or an empty vector 
(EV) as control (left panels). They were also treated with sc-514, a selective IKK2 inhibitor, or with MG-132, a 
proteasomal inhibitor (right panels). NF-ƙB activity was assessed with a) Gaussia Luciferase reporter assay using 
NF-Gluc vector and is represented as relative luminescence unit (RLU) and with b) Western blot for IƙB, 
p105/p50 and CyclinD1 as a target gene.  β-actin was used as loading control. Functional effects of IKK2 
regulation was measured on c) Proliferation assessed by BrdU incorporation assay and on d) migration assay 
with Boyden Chamber. Data are represented as mean ± SEM. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. Data shown 
are representative of three individual experiments.    
 
4.1.2  Overexpression of C-Raf activates IKK2-regulated NF-ƙB signalling pathway 
The role of IKK2 in activating NF-ƙB and subsequently affecting proliferation and 
migration, both major steps for cell transformation, indicated the role of IKK2 in tumour 
progression. It was of value before proceeding to the animal model, to investigate whether 
IKK2 activation was also observed in known SpC C-Raf BxB model in vitro. C-Raf has two main 
domains, a regulatory domain, where there is the K-Ras interaction site, and a kinase domain 
(Fig.4.4a). Deletion of the regulatory domain of C-Raf creates a constitutively active form of 
C-Raf. This truncated form is known as C-Raf BxB18. A549 cells were transfected with C-Raf 
BxB together with a reporter luciferase under the control of NF-ƙB response elements (Fig. 
4.4b). C-Raf increased the NF-ƙB activity indicating that the animal tumour model is an 
inflammatory model with increased basal NF-ƙB activity. 
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Figure  4.4 Overexpression of C-Raf BxB increases NF-ƙB activity. a) Schematic diagram of C-Raf domains (CR = 
conserved region) b) Gaussia Luciferase reporter assay using NF-Gluc vector in A549 cells transfected with C-
Raf BxB and IKK2CA. Data are represented as relative luminescence unit (RLU) as mean ± SEM. ** p ≤ 0.01, 
***p≤ 0.001. 
 
4.1.3 Changing IKK2 in alveolar type II cells affects tumour growth in SpC C-Raf BxB 
mice 
SpC C-Raf BxB mice were cross bred with mice expressing a SpC rtTA/Tet-O-IKK2CA 
(S177E, S181E), or with SpC rtTA/Tet-O-IKK2DN (D145N) to generate inducible compound 
triple transgenic mice (SpC rtTA/Tet-O-IKK2CA/SpC C-Raf BxB and SpC rtTA/Tet-O-IKK2DN/SpC 
C-Raf BxB) . Detailed information is represented in the schematic diagram in Fig. 4.5a. After 
complete lung development (5 weeks old), mice were induced with Doxycycline in the food 
to activate the transgenes. After induction for 50-56 weeks, tumour development was 
assessed via magnetic resonance imaging (MRI).  
As the BxB tumour model forms a dispersed pattern of lung adenomas, pixel image 
analysis was performed to quantify the tumour burden. Dark spaces indicate air-filled areas 
whereas grey areas are occupied by tissue. Downregulation of IKK2 in ATII cells 
(SpC/IKK2DN/BxB) reduced the tumour burden compared to SpC C-Raf BxB whereas 
SpC/IKK2CA/BxB showed higher tumour burden (Figure 4.5b). These findings were supported 
with histological examination which revealed that in mice with downregulated IKK2, 
adenomas were significantly less dispersed than in control SpC C-Raf BxB mice and in mice 
with activated IKK2 (Figure 4.5c).  
For functional quantification of the tumour burden, lung compliance was measured.  
Both resistive compliance and inspiratory capacity were reduced with increasing tumour 
burden in mice expressing C-Raf BxB (BxB) or activated IKK2 (SpC/IKK2CA/BxB) whereas tissue 
damping and elastance increased (Figure 4.5d). Downregulation of IKK2 in BxB mice rescued 
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the decreased lung compliance to a comparable level to that of control wildtype lungs. 
However, the differences between SpC C-Raf BxB control mice and SpC rtTA/Tet-O-IKK2CA 
weren’t significant. This can be explained by the fact that C-Raf itself drives NF-ƙB activation 
so further activation of the pathway didn’t show any significant additional effects. 
 
Figure  4.5 . IKK2 modulation in SpC C-Raf BxB transgenic mice. a) Schematic diagram representing the 
breeding scheme for the development of triple transgenic mice b) MRI representative images (left panel) and 
image quantification (right panel) c) Histological H&E staining of 3µm thick sections of the lung. d) Lung 
compliance measured as resistive compliance (Crs), Tissue elastance (Ers) and tissue damping (H) Data are 
represented as mean ± SEM compared to BxB. * p ≤ 0.05, ** p ≤ 0.01,. (n=5 for WT; n=3 for BxB; n=2 for 
SPC/IKK2CA/BxB and for SPC/IKK2DN/BxB). 
 
To get a closer look on the activation of NF-ƙB within the cells, lung sections were 
fluorescently immunostained with phosphorylated p65 (Ser311) and MMP9 as a selected NF-
ƙB target gene. Compound mice with activated IKK2 (IKK2CA) showed higher expression of 
both p65 and MMP9 (Figure 4.6a). Even SpC C-Raf BxB single transgenic mice showed 
substantially high expression of both p65 and its target gene MMP9 indicating the intrinsic 
effect of C-RAF on IKK2-activated canonical pathway. Furthermore, IKK2 activation promoted 
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proliferation as seen with PCNA staining. C-Raf was uniformly expressed in all groups 
(Fig.4.6b). 
 
Figure  4.6 Immunofluorescence staining of the lungs of compound mice. Representative images of lung 
sections stained with a) phosphorylated p65 (p-p65, Ser3133) and MMP9; and b) C-Raf and PCNA using DAPI as 
nuclear counterstain. Scale bar represents 50µm (n=3). 
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4.1.1 Analysis of the tumour microenvironment in IKK2-regulated SpC C-Raf BxB mice 
As the tumour microenvironment plays an important role in tumour progression, we 
postulated that changes in the host epithelial cells might influence the recruitment of 
immune cells. Upon comparison of double transgenic mice without BxB tumours, SpC/IKK2CA 
showed increased infiltration of neutrophils and dendritic cells whereas T-cells and 
macrophages were not significantly changed (Fig. 4.7a). On the other hand, in presence of C-
Raf BxB tumour burden, triple transgenic mice with IKK2CA mainly recruited more T-cells and 
neutrophils. Changes in dendritic cells and macrophages showed similar tendency though a 
closer differentiation between the subtypes of macrophages could provide a better 
understanding of the effects of immune cell recruitment (Fig. 4.7b). On the contrary, IKK2 
downregulation lead to less recruitment of all examined immune cells. However, these 
changes in the tumour microenvironment could not explain the restricted tumour growth in 
SpC/IKK2DN/BxB suggesting that the signalling changes within the host alveolar type II cells 
could be the main effector for tumour restriction. 
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Figure  4.7 Flow cytometry of different inflammatory lung cell populations. a) quantification of neutrophils, 
macrophages, T-cells and dendritic cells in double compound mice compared to wildtype mice (left panel) and 
representative histological pictures for CD11b+ cells and CD3+ cells or T-cells (right panel) b) quantification of 
neutrophils, macrophages, T-cells and dendritic cells in triple transgenic mice compared to SPC C-Raf BxB mice 
(left panel) and representative histological pictures for CD11b+ cells and CD3+ cells or T-cells (right panel). Data 
are represented as mean ± SEM. * p ≤ 0.05, ** p ≤ 0.01. Scale bar represents 50µm (n=4).  
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4.1.2 IKK2 in the lung affects its role as a metastatic niche 
The modulation of IKK2 in ATII cells outranged the effect in epithelial cells and extended 
to affect the surrounding immune environment. This is why it was of interest to investigate 
whether these changes would influence metastasis to the lung. A commonly used animal 
mouse tumour model is the xenograft subcutaneous tumour growth of Lewis Lung 
Carcinoma cells (LLC1) in C57Bl/6J mice, which have the same genetic background as the 
LLC1 cells. LLC1 cells (3x106 cells prepared in 200µl) were injected into the hind flank of 
double transgenic mice; SpC/IKK2DN and SpC/IKK2CA, along with matched wildtype controls. 
Monitoring the primary tumour growth showed no significant differences between the 
groups (Fig. 4.8a). However, mice with SpC/IKK2CA genotype carried more lung nodules than 
controls or SpC/IKK2DN (Fig.4.8b,c). This inclines that changes of IKK2 within ATII cells had 
other molecular effects that affected the susceptibility of the lung to become a metastatic 
niche for homing cancer cells.   
 
Figure  4.8 LLC1 xenograft subcutaneous model in SpC/IKK2DN and SpC/IKK2CA. a)Tumour volume of 
subcutaneous tumours measured every four days of the experiment. b) Number of nodules counted in the 
isolated lungs. Data are represented as mean ± SEM. c) Representative pictures of the isolated lung with arrows 
pointing at tumour nodules. (n=4 for SpC/IKK2DN and SpC/IKK2CA and n=5 for control group). 
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4.1.3  IKK2 regulates a panel of genes in alveolar type II cells 
Alveolar type II cells (ATII) were isolated from the lungs of adult and long-term induced 
SPC-rtTA/Tet-O-IKK2DN and SPC-rtTA/Tet-O-IKK2CA mice and age-matched wildtype mice as 
control as described in the methods section. After culturing the cells for two days, they were 
stained for SPC to check for purity (Fig. 4.9b). The isolated cells expressed surfactant protein 
C (SPC), a key marker of alveolar type II cells. ATII cells isolated from SpC/IKK2DN showed less 
nuclear p50 signal compared to control cells indicating the reduced activation of NF-ƙB 
pathway in these cells. After lysing the cells for total RNA isolation, the expression of NF-ƙB 
members was assessed. Expression of Rela, Nfkb1 and Mmp9 was downregulated in ATII 
cells of SpC/IKK2DN mice compared to wildtype or SpC/IKK2CA (Fig. 4.9c)  
 
Figure  4.9 Isolation of alveolar type II cells. a) Schematic diagram for the isolation of ATII cells b) 
Immunocytochemistry of ATII cells with SPC and p50 antibodies c) Quantitative PCR for mRNA expression 
calculated as ΔCt of the gene of interest normalized to Hprt as housekeeping gene (n=4 for WT; n=2 for 
SPC/IKK2DN; n=3 for SPC/IKK2CA). 
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The cDNA from wildtype mice and from SPC/IKK2DN was used on a RT² Profiler™ PCR 
Array Mouse Cancer PathwayFinder™ (Qiagen) which can determine the expression level of 
selected genes from various pathways involved in cancer, like growth control, apoptosis, 
angiogenesis, cell adhesion and metastasis. Based on the fold change compared to wildtype 
controls, the top ten upregulated genes and downregulated genes were selected (Table 4.1). 
From the list, those genes were selected that were novel, related to metastasis and were 
druggable.  
After screening and validation of several targets, metastasis-associated protein member 
2 (MTA2) was selected as a good candidate because it is known to be upregulated in many 
cancers and is an indicator for poor prognosis77. Interestingly, on examining the promoter of 
MTA2 for transcription factors binding sites, NF-ƙB binding sites were not found. Instead 
MTA2 promoter had binding sites for Oct factors which makes MTA2 a better candidate for 
studying. By examining the expression of MTA2 in existing mouse tumour models, KrasLA2 
and SpC C-Raf BxB, MTA2 was found to be higher expressed in both tumour types (Fig. 
4.10a). This suggests that MTA2 overexpression is an event of tumorigenesis. Interestingly, in 
human cancer cell lines, the expression of MTA2 was especially higher in those cell lines 
deriving from a metastatic site (H1437,H1299, Colo699) compared to control cell lines (BEAS-
2B and isolated human fibroblasts) as well as to the cell lines A549, A427, H1975 and H23 
which originate from primary sites (Fig. 4.10b).  
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Table 4.1 Top target genes regulated in alveolar type II cells by IKK2-downregulation compared to wildtype 
 
Gene Description Fold Change 
Binding sites to 
Transcription 
factors 
Tert Telomerase reverse transcriptase 0.014 CREB 
Tek Endothelial-specific receptor tyrosine kinase 0.119 
CREB, Oct factors, 
GATA 1 
Fgf1 Fibroblast growth factor 1 0.168 NF-ƙB 
Mmp9 Matrix metallopeptidase 9 0.304 NF-ƙB 
Pdgfa Platelet derived growth factor, alpha 0.316 NF-ƙB 
Sykb Spleen tyrosine kinase 0.339 Oct factors 
Bcl2 B-cell leukemia/lymphoma 2 0.344 NF-ƙB 
Ncam1 Neural cell adhesion molecule 1 0.346 NF-ƙB 
Twist1 Twist homolog 1 (Drosophila) 0.39 SP1 
Mta2 Metastasis-associated gene family, member 2 0.398 Oct factors 
    
 
  
Cdkn1a Cyclin-dependent kinase inhibitor 1A (p21) 1.693 SP1 
Mmp2 Matrix metallopeptidase 2 1.79 NF-ƙB 
Pdgfb Platelet derived growth factor, B polypeptide 1.79 NF-ƙB 
Myc Myelocytomatosis oncogene 1.866 CREB 
Angpt1 Angiopoietin 1 1.972 NF-ƙB 
Mdm2 Transformed mouse 3T3 cell double minute 2 2.056 Oct factors 
Itga2 Integrin alpha 2 2.789 NF-ƙB, GATA 1 
Hgf Hepatocyte growth factor 2.949 TFII 
Vegfc Vascular endothelial growth factor C 4.028 NF-ƙB 
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Figure  4.10 MTA2 expression in different mouse and human cancer types. a) Immunofluorescence of MTA2 
and IKK2 in KRasLA2 mouse lung compared to wildtype control with DAPI as nuclear stain (upper panel, scale bar 
25µm) and immunohistochemistry of MTA2 in SpC C-Raf BxB lungs and control lungs with Methyl green as 
counterstain (lower panel, scale bar 10µm) b) Western blot of various human adenocarcinoma cell lines with 
BEAS-2B (B2B) and human fibroblasts as control. Cell lines were sorted according to their isolation sites either 
primary (adenocarcinoma) or metastatic sites. β-actin was used as loading control. Representative blot of three 
experimental replicas. 
 
 
  
Results 
56 
 
4.2 MTA2 regulates NF-ƙB activity in cancer cells 
4.2.1  Is MTA2 downstream of NF-ƙB? 
To verify whether NF-ƙB had transcriptional control on MTA2, A549 cells were treated 
with LPS as a classical stimulant of the canonical NF-ƙB pathway at two different 
concentrations. The expression of NF-ƙB target gene MMP9 was increased in response to 
LPS, and the stimulatory effect subsided with time. Surprisingly, the levels of MTA2 declined 
unlike the expression of target genes, or of NFKB1 and RELA (Fig. 4.11a). Even on protein 
level, the stimulation with TNFα failed to produce substantial changes in MTA2 levels. The 
minute increase in nuclear MTA2 levels after treatment was not proportional to the strong 
nuclear translocation of p50/p65 (Fig. 4.11b). Finally, to verify whether the irresponsiveness 
of MTA2 to extrinsic stimulus is specific to NF-ƙB pathway, MTA2 expression was checked in 
A549 overexpressing IKK2CA. In corroboration with the data observed upon LPS stimulation, 
MTA2 was downregulated in these cells compared to control A549 or A549 carrying the 
empty vector (Fig. 4.11c). 
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Figure  4.11 Expression of MTA2 upon activation of NF-ƙB pathway. a) RNA expression in A549 after 
stimulation with LPS at 5µg/ml and 10µg/ml for 6h, 12h and 24h calculated as ΔCt of the gene of interest 
normalized to HPRT as housekeeping gene. Data are represented as mean ± SEM. * p ≤ 0.05, ** p ≤ 0.01, **** 
p ≤ 0.001. b) Western blot of cytoplasmic and nuclear fractions of A549 cells stimulated with TNFα (5ng/ml).    
c) Western blot of A549 overexpressing IKK2CA or the empty vector (EV) with β-actin as loading control. 
Representative blot of three experimental replicas. 
 
Furthermore, LLC1 cells were checked for NF-ƙB activity. Similar to human cancer cell 
lines it showed basal NF-ƙB activity and thus LLC1 cells were treated with a panel of classical 
IKK2 inhibitors: sc-514, Bay11-7085, Parthenolide, and with the general proteasomal 
inhibitor MG-132. This treatment not only decreased NF-ƙB activity measured by a reporter 
assay with NF-Gluc (Fig. 4.12a) but strikingly MTA2 expression was downregulated (Fig. 
4.12b).  
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Figure  4.12 Expression of MTA2 upon downregulation of NF-ƙB pathway in LLC1 cells. LLC1 cells were treated 
with sc-514 (12.5μM and 25μM), Parthenolide (10μM and 20 μM), Bay11-7085 (5μM and 10μM) or MG-132 
(25μM) for 24h. a) NF-ƙB activity assessed with Gaussia Luciferase reporter assay using NF-Gluc vector and data 
is represented as relative luminescence unit (RLU). b) mRNA expression of MTA2 calculated as ΔCt normalized 
to Hprt as housekeeping gene. Statistical analysis was performed using DMSO as control. Data are represented 
as mean ± SEM. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 compared to vehicle control (DMSO). 
 
4.2.2  MTA2 downregulates NF-ƙB activity 
As the response of MTA2 to stimulants and inhibitors of NF-ƙB pathway was ambiguous, 
it was less likely that MTA2 is downstream of NF-ƙB. To verify whether MTA2 affects NF-ƙB 
signalling, MTA2 was overexpressed in human A549 and RNA expression revealed a decline 
in the expression of RELA and FN1. However, the overexpression of MTA2 lead to the 
downregulation of MTA1 inclining a possible complementary effect (Fig.4.13a). On the other 
hand, MTA family gene member 3 (MTA3) was not affected at all (Data not shown). A 
significant decline in NF-ƙB activity was also observed upon co-transfection of MTA2 and NF-
Gluc, a Gaussia luciferase reporter. The decline in activity through MTA2 was stronger than 
that caused by IKK2 inhibitors, sc-514 and MG-132, suggesting a stronger or more 
downstream regulatory mechanism of MTA2 on NF-ƙB. Even the stimulatory effect of LPS 
was almost completely reversed in presence of MTA2 (Fig. 4.13b). In order to check whether 
this inhibitory effect was specific to A549 cells, other cancer cell lines (A427 and H460) as 
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well as HEK as control were transfected with MTA2 and in all cell lines tested, a significant 
reduction of NF-ƙB activity was observed (Fig. 4.13c). However, the reduction of NF-ƙB 
activity in cancer cell lines were stronger than in HEK cells disposing a sturdier role in cancer 
compared to normal cells. 
 
 
Figure  4.13 Effect of MTA2 overexpression on NF-ƙB activity. a) A549 mRNA expression of MTA2 family and 
target genes of NF-ƙB calculated as ΔCt and normalized to HPRT as housekeeping gene. Data are represented 
as mean ± SEM. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. NF-ƙB activity via Gaussia Luciferase reporter assay in b) 
A549 after treatment with LPS (5μg/ml), sc-514 (25μM) and MG-132 (25μM) and co-transfection with MTA2 for 
24h and in c) various cell lines. Data is represented as relative luminescence unit (RLU). 
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Similar behaviour was observed in mouse LLC1 cells upon overexpression MTA2 even when 
examining a panel of target genes (Fig. 4.14). Effects on different target genes were 
summarized in Table 4.2.  
 
Figure  4.14 Effect of MTA2 overexpression in LLC1 cells.  LLC1 cells were transfected with MTA2 for 24h before 
the isolation of RNA. RNA expression was assessed by quantitative PCR of a) genes of MTA family b) genes of 
the NF-ƙB family and the IKK regulating it c) target genes of NF-ƙB which were regulated by MTA2 d) target 
genes of NF-ƙB which were not regulated by MTA2. Data was calculated as ΔCt, normalized to Hprt as 
housekeeping gene and represented as mean ± SEM. * p ≤ 0.05, ** p ≤ 0.01. Representative data of three 
individual experiments. 
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Table 4.2 Genes regulated by overexpression of MTA2 in relation to NF-ƙB pathway.  
a) Known NF-ƙB target genes, b) Non-target genes of NF-ƙB regulated by MTA2 
a. 
Gene Name & Role Regulation by MTA overexpression 
   
Ccnd1 Cyclin D1; Cell-cycle regulation ↓ 
Cdkn1a p21; cyclin-dependent kinase inhibitor 1; Cell-cycle regulation  ↓  
Fn1 Fibronectin; Extracellular attachment ↓↓↓ 
Mmp9 
Matrix metalloproteinase 9; cell adhesion ; secreted collagenase 
involved in metastasis ↓↓↓ 
Myc C-myc; Proto-oncogene ↓↓↓ 
Ncam1 Neural cell adhesion molecule Not regulated 
Nfkb1 Nuclear factor kappa B; inflammation ↓↓↓ 
Rela V-Rel avian reticuloendotheliosis viral oncogene, homologue A ↓↓↓ 
Twist1 Transcription repressor Not regulated 
Vegf c Vascular Endothelial Growth Factor; angiogenesis Not regulated 
 
b. 
Gene Name & Role Regulation by MTA overexpression 
    Ki67 Antigen identified by monoclonal antibody Ki-67  (All phases except Go); proliferation 
↑↑↑ 
    Pcna Proliferating cell nuclear antigen (Phase S) ; proliferation ↑↑↑ 
    Cdkn1b p27; Cell cycle-dependent kinase inhibitor; proliferation Not regulated 
    Raf1 C-Raf; Proto-oncogene serine/threonine-protein kinase  
(Mitogenic cascade); proliferation Not regulated 
    Cdh1 E-Cadherin; epithelial marker; Epithelial-mesenchymal transition Not regulated 
    Tgfb Transforming growth factor beta 1, Epithelial-mesenchymal transition ↓↓↓ 
    Mmp2 Matrix metalloproteinase 2; cell adhesion & angiogenesis Not regulated 
    Vegfa Vascular endothelial growth factor A; angiogenesis ↓↓↓ 
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4.2.3 MTA2 and members of the NuRD complex interact with p50/p65 complex 
MTA2 is known to be a part of the nucleosome and histone deacetylase remodelling 
(NuRD) complex68. This complex was shown to interact with different transcription factors to 
repress their transcriptional activity. To check whether NF-ƙB members and MTA2 are 
interacting within the cancer cells, cytoplasmic and nuclear proteins were isolated from 
A549 cells. The protein fractions were pulled down with p65 and MTA2. Western blots 
revealed the binding of p65 to MTA2 and HDAC1, another component of the NuRD complex. 
This binding was missing in the nuclear fraction when cells were treated with sc-514, an 
inhibitor known to prevent the nuclear translocation of p50/p65 (Fig.4.15a upper panel). 
Similarly when cells were stimulated with LPS and TNFα, pulldown with MTA2 co-
precipitated p65 indicating a possible interaction between of the two proteins (Figure 4.15a 
lower panel).  
In order to show whether this interaction is direct, proximity ligation assay (PLA) was 
performed using antibodies against MTA2 and phosphorylated RelA/p65 (Ser311). This assay 
can detect proteins which are in close proximity to each other in a range of 40nm. In A549 
overexpressing IKK2CA there was significant nuclear signal of the proximity of both proteins. 
This signal was specific as overexpression of MTA2 clearly increased it whereas knocking 
down MTA2 via shRNA barely showed any interaction (Fig.4.15b). Collectively, these data 
suggest an interaction of both NF-ƙB and NuRD complexes.  
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Figure  4.15 Interaction of RelA/p65 and MTA2 in A549 cells. a) Co-immunoprecipitation of A549 using 
pulldown with p65 after treatment with LPS and 25µM sc-514 (upper panel) and b) pulldown with MTA2 after 
stimulation with LPS and TNFα. b) Proximity ligation assay (PLA) using antibodies against MTA2 and 
phosphorylated RelA/p65 (Ser311) of control cells and A549 overexpressing IKK2CA (upper panel; scale bar 
represents 50µm at a magnification of 20x) and of cells overexpressing MTA2 or have knockdown of MTA2 
(lower panel; scale bar represents 25µm at a magnification of 40x). 
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For a better understanding on the effects of such interaction on the activities of NF-ƙB 
complex as well as on the NuRD complex, H1650 cells were treated with LPS (10μg/ml) or 
TNFα (5ng/ml) for 6h after which the nuclear lysate of cells was prepared. Using a sucrose 
gradient, the nuclear lysate was fractionated via ultracentrifugation to obtain various 
nuclear complexes. Different components of both complexes were detected in selected 
fractions as shown in Fig 4.16a-c. 
Both members of the NF-ƙB heterodimer were detected in fractions 7-15 where p65 
showed strongest peak in fraction 13 in control, LPS and TNFα conditions. On the other 
hand, p50 was higher in control samples rather than in LPS or TNFα stimulation, assumingly 
due to the fact that p50 homodimer is known to act as repressor. Upon stimulation the 
amount of p50 was relatively reduced being solely contributing in the active heterodimer. 
Looking on the members of the NuRD complex, they were detected in fractions 5-17. MTA2 
peaked in fraction 7 in all conditions but was more expressed in the control sample. HDAC1 
rather peaked in fraction 9 but interestingly there was another band detected only in the 
stimulated conditions. HDAC2 was relatively constant in all fractions 5-17 with a slight peak 
in fraction 7. Furthermore, CHD4 correlated with MTA2 as it was higher in the control 
samples compared to stimulated conditions.  The protein p300 was also detected in the 
same fractions albeit didn’t correlate with HDAC1 acetylation.  
To correlate the presence of the individual members with the activity of each complex, 
NF-ƙB and pan-HDAC activity assays were performed. NF-ƙB activity was measured based on 
p65 binding to NF-ƙB binding domain. In LPS and TNFα stimulated fractions, more activity 
was observed in input as well as in fractions 7-15 peaking at fraction 13 (Fig. 4.16d). 
Interestingly, HDAC activity was decreased upon stimulation in the input. In the first fraction, 
there was increased HDAC activity that seemed to be independent of NF-ƙB heterodimer. 
Fraction 9 showed significant decrease in HDAC activity upon stimulation, whereas fraction 7 
showed increased HDAC activity upon LPS stimulation (Fig. 4.16e).  
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Figure  4.16 Fractionation of nuclear lysates after stimulation with LPS or TNFα. H1650 cells were treated with 
LPS (10μg/ml) or TNFα (5ng/ml) for 6h. Nuclear lysates were isolated and fractionated using a sucrose gradient. 
Odd fractions were analysed on Western blot (a-c), for NF-ƙB activity (d) and for HDAC activity assay (e). Data 
represented as mean ± SEM. ** p ≤ 0.01, *** p ≤ 0.001, ****p≤ 0.0001 compared to control sample of 
individual fractions. 
 
4.2.4 MTA2 and CHD4 act as repressor of p50/p65 dimer 
Taken together these data showed that the NuRD complex and p50/p65 interact in the 
nucleus and that this interaction affected the activation status of NF-ƙB. To verify the 
specificity of this interaction, MTA2 and CHD4 were overexpressed in A549 cells together 
with NF-Gluc to measure NF-ƙB activity. Both MTA2 and CHD4 overexpression decreased NF-
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ƙB activity whereas knockdown of these genes via shRNA increased the NF-ƙB activity (Figure 
4.17).   
 
Figure  4.17 NF-ƙB activity repression via MTA2 and CHD4. Gaussia Luciferase reporter assay in A549 after 
overexpression and knockdown of MTA2 (a) and CHD4 (b) compared to overexpression of IKK2CA. Data is 
represented as relative luminescence unit (RLU) normalized to EV. Data represented as mean ± SEM. * p ≤ 0.05, 
*** p ≤ 0.001 compared to empty vector (EV) as control.  
 
The NuRD complex is reported to interact with the promoter region of various genes, 
e.g. E-Cadherin, leading to its deactylation and thus subsequent deactivation96. In order to 
assess whether the NuRD complex is recruited to the promoter of NF-ƙB or other target 
genes, chromatin immunoprecipitation was performed. A549 cells were stimulated with LPS 
to estimate the preferential binding of MTA2. Two known target genes of NF-ƙB were 
selected: NFKB1 itself and NFKBIA known as IƙB1a. The binding sites of the used primers are 
illustrated in Fig. 4.18a. Both promoters showed enrichment for RelA/p65 upon stimulation 
with LPS (Fig. 4.18b). However, the binding of MTA2 was only observed with NFKB1 
upstream promoter and to a very slight extent on NFKBIA promoter. Interestingly, the 
binding of MTA2 was stronger in control sample compared to LPS-stimulated cells. 
In order to confirm the obtained results, A549 cells were treated with TNFα. Another 
member of NuRD complex was included, namely retinoblastoma binding protein 7, known as 
RbAp46, together with p50 for the pulldown. There was a slight enrichment of MTA2 and 
RbAp46 in control samples over treated ones. The binding to different promoter regions 
differed between LPS and TNFα inclining that every stimulant has its unique binding 
mechanism and kinetics. LPS stimulation showed stronger enrichment for the NFKB1 
proximal primer for RelA/p65 whereas TNFα stimulation recruited more RelA/p65 to the 
upstream region of NFkB1 promoter (Fig. 4.19a). Surprisingly, when the experiment was 
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repeated in HEK cells the enrichment of MTA2 and RbAp46 was much stronger in control 
state compared to stimulated condition (Fig. 4.19b).  
 
 
Figure  4.18 Chromatin Immunoprecipitation in A549 cells treated with LPS. a) Schematic representation of the 
ChIP primers binding sites. ChIP pulldown was done using antibodies against RelA/p65 and MTA2 and a 
corresponding rabbit IgG as control. RT-qPCR was performed using primers in the promoter region of NFKB1 
and NFKBIA. Data was normalized to the respective input and represented as percentage input. 
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Figure  4.19 Chromatin Immunoprecipitation after TNFα stimulation. ChIP pulldown was performed in a) A549 
cells b) HEK cells using antibodies against p50, RelA/p65, MTA2 and RbAp46 and a corresponding IgG as 
control. RT-qPCR was performed using primers in the promoter region of NFKB1 and NFKBIA. Data represented 
as mean ± SEM. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 Data was normalized to the respective input and 
represented as percentage input (n=3). 
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4.3 Effect of IKK2CA overexpression and knockdown of MTA2 on tumour growth 
4.3.1  Generation of stable LLC1 cells with shMTA2 and IKK2CA & their 
characterization 
After showing the possible regulation of NF-ƙB by MTA2 and the NuRD complex, it was 
of interest to show how knocking down MTA2 would affect tumour growth. For this purpose, 
LLC1 cells were transfected with pCDH-GFP empty vector, pCDH-GFP-IKK2CA and shMTA2. 
Transfected cells were characterized for their NF-ƙB activity by transiently transfecting them 
with NF-GLuc. Both IKK2CA overexpression and the knockdown of MTA2 showed increased 
activity compared to their respective controls (Fig. 4.20a). Furthermore, the cells were 
assessed for their migratory capacity via the Boyden chamber assay, where MTA2 
knockdown significantly increased the number of migrated cells (Fig. 4.20b). Finally, in order 
to evaluate the ability of these cells to grow independent of anchorage, soft agar assay was 
performed. Cells with shMTA2 formed big colonies, even bigger than those formed by LLC1-
IKK2CA cells (Fig. 4.20c). 
 
Figure  4.20 Characterization of LLC1 cells transfected with IKK2CA and shMTA2. a) Gaussia Luciferase reporter 
assay. Data is represented as relative luminescence unit (RLU) as mean ± SEM compared to empty vector (EV) 
as control and to LLC1 control, respectively. b) Boyden Chamber migration assay of control LLC1 cells and LLC1-
shMTA2. c) Soft agar assay showing representative colonies at Day 14 (left panel, scale bar represents 100µm). 
Quantification of the size of colonies represented as average area (right panel). ** p ≤ 0.01, *** p ≤ 0.001 
(n=4). 
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4.3.2 Subcutaneous tumour xenograft mouse model with LLC1 cells 
Mice were injected subcutaneously with 3x106 cells in 200µl with different LLC1 cells; 
LLC1-EV, LLC1-IKK2CA and LLC1-shMTA2. Measuring the tumour size revealed an increase of 
tumour upon silencing MTA2 even to a greater extent compared to LLC1 cells with IKK2 
activation. The tumour weight was also significantly increased in the group with LLC1-
shMTA2 (Fig. 4.21). 
 
Figure  4.21 Tumour growth of subcutaneous xenograft model of LLC1-EV, LLC1-IKK2CA and LLC1-shMTA2.  
a) Representative pictures of the subcutaneous tumour at endpoint of the experiment. b) Diagram showing the 
percentage of tumour weight normalized to whole body weight. Data is represented as mean ± SEM. * p ≤ 0.05, 
*** p ≤ 0.001 compared to empty vector (EV) as control (n=6-8/group). 
 
The subcutaneous tumours were dissected and the RNA isolated. Surprisingly, knocking 
down MTA2 increased the expression of Ikbkb (IKK2) though it is not a known target gene of 
p50/p65 suggesting that MTA2 might play a role in the overall NF-ƙB activation. 
Furthermore, despite of the moderate increase of IKK2 expression in LLC1-IKK2CA and LLC1-
shMTA2, the effects observed in the downstream target genes were stronger though the 
levels of MTA2 were upregulated (Fig. 4.22a). On the other hand, based on the mRNA 
expression, NF-ƙB members, p50 and p65, were upregulated upon overexpression of the 
activated form of IKK2 and to a greater extent in cells with knocked down MTA2. Nfkbia 
known as IkB1α which is known to regulate p50/p65 and is also a target gene was 
significantly upregulated in both LLC1-IKK2CA and LLC1-shMTA2 (Fig. 4.22b). A similar pattern 
was observed with several target genes of NF-ƙB including Tnf, Nfkbia, Mmp9, Ccnd1, 
Cdkn1a and Cdkn1b (Fig. 4.21c).  This observation goes in concordance with the in vitro 
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studies showing a repressing effect of MTA2 on the activity of NF-ƙB and the expression of 
its target genes.  
 
 
Figure  4.22 Expression profile from mRNA of subcutaneous tumours. mRNA expression was assessed by 
quantitative PCR of a) Ikbkb and Mta2  b) genes of the NF-ƙB family c) target genes of NF-ƙB which were 
regulated by MTA2. Data was calculated as ΔCt, normalized to Hprt as housekeeping gene and represented as 
mean ± SEM. * p ≤ 0.05, ** p ≤ 0.01, ***p≤0.001. (n=6-8/group)  
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For a closer look on the cells within the tumour and their respective expression of 
RelA/p65 and MTA2, isolated tumours were fixed and sectioned for staining. 
Immunofluorescence staining clearly showed an activation of NF-ƙB pathway seen as nuclear 
translocation of RelA/p65 in cells with IKK2CA and shMTA2 compared to control cells (Figure 
4.23, middle panel). Interestingly, the expression of MTA2 in IKK2CA cells appeared higher in 
contrast to what was observed in vitro, where overexpression of IKK2CA showed less MTA2 
on protein level (Fig.4.11c). Besides, there was still residual expression of MTA2 in cells with 
shMTA2 (Fig. 4.23, upper panel) that was also observed in the mRNA expression. At this 
point it is worth mentioning that the silencing of MTA2 was not complete in LLC1 cells. Both 
observations indicate that the in vivo system, where there are other cell types contributing 
to the tumour microenvironment, might have influence on the tumour behaviour. 
 
 
Figure  4.23 Immunofluorescence of subcutaneous tumour sections. Representative images showing MTA2 
(green) and nuclear translocation of RelA/p65 (red) with DAPI as nuclear counterstain. Scale bar represents 
25µm. 
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Hence, part of the tumours were digested and analysed by flow cytometry for the 
immune cell repertoire using a panel of immune cell markers depicted in Fig. 4.24a. Flow 
cytometric analysis revealed that B lymphocytes (Fig. 4.24b, upper panel) which are known 
to be pro-tumorigenic were significantly higher in LLC1-shMTA2 cells. This can explain the 
bigger tumour size produced by this cell type. Moreover, T cells, T regulatory cells, CD4+ cells 
and CD8+ T-lymphocytes were reduced in bigger tumours of both IKK2CA and shMTA2. 
Strikingly, the subcutaneous tumour of LLC1-shMTA2 and LLC1-IKK2CA harbored more MHC-
II- TAMs and less MHC-II+ TAMs compared to control cells. Taken together, the flow 
cytometric analysis suggested a more tumour-favourable immune microenvironment in the 
tumours originating from LLC1 with knockdown of MTA2 or activation of IKK2. These data 
support the pro-tumorigenic effects of NF-ƙB pathway and highlight the potential role of 
MTA2 in regulating these effects. 
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Figure  4.24 Flow cytometry of immune cells repertoire in LLC1 subcutaneous tumours. a) Schematic diagram 
of the gating strategy using the different immune cell markers b) Quantification plots of different immune cells 
calculated as percentage of total CD45+ cells. Data represented as mean ± SEM. * p ≤ 0.05, ** p ≤ 0.01, 
***p≤0.001. (n=4/group). 
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5 Discussion 
Inflammation and cancer were linked more than a century ago when Rudolf Virchow 
identified leukocytes infiltration in neoplastic tissues97. Many years of research followed 
until the discovery of NF-ƙB three decades ago which paved the way to more insight into the 
contribution of inflammatory signalling to cancer development. NF-ƙB is not only involved in 
innate and adaptive immune responses but it governs the expression of wide set of diverse 
genes regulating cell growth and adhesion, cell cycle regulation, apoptosis, angiogenesis – all 
established hallmarks of neoplastic transformation47, 52. Many tumours, especially solid 
tumours, exhibit constitutive activation of NF-ƙB canonical signalling pathway. This fact 
encouraged several researchers to develop NF-ƙB inhibitors and IKK2 inhibitors as adjunct 
therapy to existing cancer treatment modalities, however, with modest success. More 
studies are required for a better understanding of NF-ƙB activation in cancer and the 
underlying regulatory mechanisms.  
5.1 Aberrant NF-ƙB activity in lung cancer 
5.1.1 Basal expression of NF-ƙB in different cancer cell lines 
Basal NF-ƙB activity was detected in several lung adenocarcinoma cell lines (A549, A427, 
Colo699, H1650, and H2122) as well as non-tumour cell line (BEAS-2B). NFKB1, RELA and 
MMP9 expression levels were lowest in BEAS-2B control cells compared to tumour cell lines 
though almost all cell lines showed increased expression levels of these genes upon LPS 
stimulation. This goes in concordance with several other studies which show a correlation 
between elevated NF-ƙB activation and cancer progression98. 
Both LPS and TNFα induced NF-ƙB nuclear translocation and subsequent activation 
varied between cell lines. The differences in the strength of the response probably refer to 
different activation kinetics, stimuli used and target genes examined. Another important 
parameter playing a role in NF-ƙB activation is the binding of IƙB proteins to NF-ƙB and the 
formation of IƙB/NF-ƙB complexes. Such association not just masks the nuclear localization 
signal (NLS) of NF-ƙB but also allows its export from the nucleus. These shuttling processes 
together with binding and dissociation contribute to the basal activity within the cells and 
affect their response to stimuli26. Even in H2122 cells, where the expression of NF-ƙB target 
genes was marginally affected on RNA level, a clear nuclear translocation was observed 
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within the cells (Fig.4.1 and Fig 4.2). This indicates that there are different levels of NF-ƙB 
activation and that the transcriptional activation varies between target genes examined 
(NFKB1, RELA, MMP9 and FN1). Tobar et al. demonstrated that TGF-β1-mediated cell 
invasion and migration regulates MMP9 expression through the activation of NF-ƙB via Rac1-
ROS mechanism. Inhibition of NF-ƙB and reactive oxygen species (ROS) hampers TGF-ß1-
mediated EMT99. Whole genome data analysis attempted to identify cancer subtypes by 
their genetic signature. In this respect Guan et al. identified NFKB and FN1 as markers for 
ovarian cancer100. 
However, it is necessary to differentiate between the different members of NF-ƙB and 
the distinct complexes they form. Whereas p50/p65 heterodimer was linked to activation, 
the p50 homodimer plays an opposite role. The presence of p50 in the nucleus was 
identified in LPS intolerance and is associated with inactivation if present as p50-homodimer. 
As p50 is devoid of the transactivating domain (TAD), its presence in the nucleus rather 
blocks access of the active heterodimer to NF-ƙB binding sites83.  
5.1.2 Activity of NF-ƙB in SpC C-Raf BxB mouse model 
In the used transgenic mouse model, C-Raf BxB is expressed constitutively under the 
control of SpC promoter.  Similar to several cancer models, like K-Ras and B-Raf models, SpC 
C-Raf BxB has an activation mutation in the mitogenic cascade101, 102. Such genetic 
abnormalities in epithelial cells (e.g. K-Ras mutation identified in 25-40% of lung cancer 
samples and in several other tumour types) encourage activation of NF-ƙB103. In vitro in A549 
cells, C-Raf BxB exhibited high NF-ƙB activity similar to the activation induced by IKK2 
(Fig.4.4b). This was observed in several other models; in a mouse model of precancerous 
pancreatic lesions Daniluk et al. showed that oncogenic Ras initiate a positive feedback loop 
of NF-ƙB activation that further pathologically activates Ras. Inhibition of Cox-2 interrupted 
this loop and attenuated the inflammatory and oncogenic stimuli104. Previous studies 
showed that C-Raf doesn’t directly activate IKK complex but its activation is rather conveyed 
indirectly by another membrane shuttle kinase known as MEKK121. 
Diverse mutations, genetic deletions and amplifications, as well as chromosomal 
translocations observed in different lymphoid cancers, like Hodgkin lymphoma and  B cell 
lymphoma, were supported  by constitutive activation of NF-ƙB103. Most of the reported 
aberrant NF-ƙB activity in cancer was related to IKK2 canonical signalling.  
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5.2 Role of IKK2 in lung cancer progression 
IKK2 is a kinase member of the trimeric IKK-complex involved in the activation of NF-ƙB 
in the canonical signalling pathway32. This upstream kinase is stimulated by several cytokine 
and growth-inducing signals to phosphorylate IƙB, sequestering p50/p65 to the cytoplasm in 
unstimulated state, so that NF-ƙB complex becomes free to shuttle to the nucleus.  
5.2.1 NF-ƙB activation depends on IKK2 pathway 
The functional effects of NF-ƙB activation were reflected in increased proliferation and 
migration. Specific IKK2 inhibitors like sc-514, parthenolide or Bay11-7085 as well as MG-132 
showed reduction in both the proliferative and migratory capacity of cells indicating the 
pivotal role of IKK2 activation in cancer cells. Several IKK2 inhibitors were thus studied in 
different cancers; a pharmaceutical IKK2 inhibitor AS602868 was shown to inhibit growth of 
multiple myeloma cells in vitro105. A recent study by Deng et. al showed the beneficial 
cytotoxic effect of the novel IKK2 inhibitor LY2409881 in a preclinical model of lymphoma. 
They suggest the use of LY2409881 together with HDAC inhibitor romidepsin for the 
treatment of B- and T-cell lymphoma106. 
5.2.2 IKK2 modulation in SpC C-Raf BxB tumour model 
In corroboration with data obtained in vitro, the SpC C-Raf BxB animal model confirmed 
the impact of IKK2 on tumour growth. Mice with SpCrtTA/IKK2DN/SpC C-Raf BxB genotype 
showed less tumour dispersion than SpC C-Raf BxB mice and their IKK2CA-counterparts. The 
reduction in tumour was also reflected in improved lung compliance similar to that observed 
in matched wildtype controls. However, the differences between SpC C-Raf BxB mice and 
SpC rtTA/Tet-O-IKK2CA were not significant. This can be explained by the fact that C-Raf itself 
drives NF-ƙB activation so further activation of the pathway did not show any significant 
additional effects. Looking closer at the compliance data in mice with IKK2DN, it was noticed 
that tissue elastance (Ers) and tissue damping (H) were even less than in wildtype controls. 
This can be due to the loss of alveolar structure observed in SpCrtTA/IKK2DN/SpC C-Raf BxB 
lungs producing an emphysema-like effect. A study by Xia et al. reported that IKK2 depletion 
in mouse lungs lead to reduced tumour proliferation mediated by a reduction in the Timp-1 
expression.  Timp-1, a known target gene of NF-ƙB, is required for Erk signalling activation 
and consequent cell proliferation107.  
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The activation of NF-ƙB was also assessed immunohistochemically using an antibody 
against phosphorylated RelA/p65 at Ser311. The expression of p-p65 (Ser311) was reduced 
upon downregulation of IKK2 in BxB lungs, whereas in SpC/IKK2CA/BxB p-p65 was very strong 
compared to SpC C-Raf BxB. Phosphorylation at Ser311 is known to occur in response to 
TNFα stimulation where it facilitates the recruitment of the co-activator CBP and enforces 
the interaction between RelA/p65 and CBP. The responsible kinase is the atypical protein 
kinase PKCζ38. Other phosphorylation sites on RelA/p65 are targeted by several kinases 
including IKK2. A better analysis of phosphorylation and other post-translational 
modification of different members of NF-ƙB will give more insight into the dynamics of their 
transcriptional activation. 
The vast variety of post-translational modifications can be one reason why IKK2 alone 
wasn’t sufficient to tightly regulate NF-ƙB activation. Many studies showed the tumour 
inhibitory effect of IKK2 inhibition in several cancer types, however, IKK2 inhibitors showed 
modest clinical efficacy108. Clinical studies suggest the necessity to differentiate between 
anti-apoptotic and pro-apoptotic roles of NF-ƙB by defining the biological context before 
therapy, or suggest the treatment by NF-ƙB inhibitors only for short duration either alone or 
in conjunction with other therapeutics95, 109. IKK2 not only regulates NF-ƙB but also has NF-
ƙB-independent effects leading to several off-target effects. Chariot reported that IKK 
subunits can phosphorylate essential targets like FOXO3a and p53 through NF-ƙB-
independent pathways110. A more extensive understanding is still required to dissect the role 
IKK-complex in tumour development.  
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5.3 MTA2 expression in tumours 
In order to analyse the molecular impact of altering IKK2 in mouse lungs, alveolar type II 
cells were isolated from SpC-rtTA/Tet-O-IKK2DN and wildtype lungs to compare the 
expression of major genes known to play a role in carcinogenesis. MTA2 was identified as 
one of the highly affected genes (Table 4.1). Its expression was high in lung tumours of both 
KrasLA2 and SpC C-Raf BxB lung tumours. It is noteworthy that in animal mouse models, 
mutations of both Kras and Tp53 in the lung lead to the formation of aggressive metastatic 
lesions though Kras mutations alone merely formed adenocarcinomas111. SpC C-Raf BxB 
leads to the formation of benign adenomas. This suggests that MTA2 overexpression is an 
early event of tumorigenesis.  
When comparing expression of MTA2 in different lung adenocarcinoma cells lines, 
immunoblots showed that cell lines originating from a metastatic site (e.g. H1437, H1299 
and Colo699) expressed more MTA2. An additional band of higher molecular weight was 
observed in these cell lines but was almost absent in cells isolated from primary sites (e.g. 
A549, A427, H1975 and H23). This band could represent the acetylated form of MTA2 which 
is reported to be the activated form of the protein. Histone acetyltransferase p300 
acetylates MTA2 at K152 which promoted growth and migration of colorectal cancer cells112. 
Hitherto, several studies correlated the overexpression of MTA2 with poor prognosis in 
different cancer types, like lung cancer113, colorectal cancer114 and oestrogen receptor-
negative breast cancer115. 
5.4 MTA2: a regulator of NF-ƙB activity 
MTA2 builds a complex together with HDAC1/2, CHD4 and structural components, such 
as RbAp46, to form the NuRD complex. Most studies correlate NuRD complex association 
with transcriptional repression though lately there is increasing evidence on the activating 
potential of NuRD binding to promoters116-118. In human as well as mouse cells, MTA2 
overexpression reduced NF-ƙB activity as seen by reporter assay and on RNA expression 
levels of selected NF-ƙB target genes.  
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5.4.1 MTA2/NuRD interacts with NF-ƙB 
Both p50/p65 members and HDAC1 and MTA2 were bound together as seen by 
immunoprecipitation with both p65 and MTA2. Seemingly this interaction is direct as PLA 
could detect both MTA2 and p-p65 within a distance of 40nm. The interaction was almost 
exclusively in the nucleus in A549 cells overexpressing IKK2CA whereas overexpression of 
MTA2 showed nuclear as well as cytoplasmic interaction. In literature, there is scrutiny 
concerning the subcellular localization of MTA2. While most reports showed nuclear 
localization119, 120, Lui et al. revealed immunohistological proof of both nuclear and 
cytoplasmic distribution 77.  On the other hand, MTA1 was shown to localize both in the 
nucleus and in the cytoplasm, where it regulates -among other functions- the cytoskeletal 
structure79. Whether MTA2 plays a similar role and localizes to microtubules still has to be 
studied.  
Further correlation of nuclear fractions with the respective NF-ƙB and HDAC activity 
assays demonstrated that there is an inverse relation. Where treatment with LPS or TNFα 
increased NF-ƙB activity, HDAC activity declined with treatment as seen in input samples. In 
addition, fractions with high NF-ƙB activity (F9-13) showed lower HDAC activity (Fig 4.16). 
Surprisingly, fraction 7 showed increased HDAC activity upon LPS stimulation. This could be 
related to the role of p50 as repressor. The p50-homodimer acts as repressor for NF-ƙB 
pathway because, unlike p65 and RelB, p50 lacks the transactivation domain so it binds to 
the promoter blocking activation via p50/p6583, 121.  Previously it was reported that 
p50/HDAC1 interaction plays a role in LPS tolerance and the attenuation of its stimulatory 
effect83. It is worth mentioning that the kit used for the assay detects all HDACs except for 
sirtuins. Further experiments should be performed to exclusively determine the activation 
status of HDAC1/2.  
Immunoblots of the various fractions showed a double band of HDAC1 in samples 
treated with either LPS or TNFα. This band, observed mainly in fractions 13 and 15, could 
refer to the acetylated form of HDAC1 which is reported to be inactive70. In case of MTA2, a 
band was detected with higher molecular weight, which could refer to posttranslational 
modification of MTA2. It was reported that p300 is responsible for the acetylation of MTA2, 
a modification correlating with increased NuRD complex activity112. 
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5.4.2 MTA2 binds to promoters of NF-ƙB target genes 
MTA2/NuRD complex as well as p50/p65 binding was identified in the promoter region 
of NFKB1 and NFKBIA genes, both target genes of NF-ƙB, as seen by ChIP in both A549 and 
HEK cells. For NFKB1 gene, two promoter regions were examined, NFKB1 proximal at -28 and 
NFKB1 upstream at -2341. Interestingly, MTA2 was enriched at the upstream region whereas 
RelA/p65 bound to both regions yet stronger to the proximal region in both A549 and HEK 
cells. However, the response to stimuli was different in A549 paralleled to HEK cells. 
Stimulation with LPS and TNFα showed higher enrichment of RelA/p65 and p50 in A549 at all 
tested sites compared to control cells. On the contrary, stimulation with LPS showed lower 
enrichment of MTA2 on NFKB1 upstream and NFKBIA promoter region compared to control 
suggesting a repressing effect of MTA2 in unstimulated state. This effect was not as evident 
upon stimulation with TNFα in A549 cells. In contrast, TNFα stimulation in HEK cells revealed 
a lower enrichment of both MTA2 and RbAp46 at NFKB1 proximal and NFKBIA promoter 
region compared to control condition. This could be explained by the fact that cancer cells 
like A549 already have higher basal NF-ƙB activity which means that even in unstimulated 
state there is already promoter activity. In order to confirm this assumption more 
experiments should be performed to compare different normal cells with various cancer cell 
lines. Furthermore, it is of interest to determine the kinetics of such interaction together 
with the examination of more NF-ƙB target genes. 
Several studies have described the repressive effects of NuRD complex in different 
cancer types. An interesting study by Fu et al. showed that TWIST, an oncogene playing an 
essential role in epithelial mesenchymal transition, binds and interacts with NuRD complex 
and recruits it to the promoter of E-cadherin. This recruitment results in the repression of E-
Cadherin expression and facilitates the switch to a metastatic mesenchymal phenotype96. 
Another study in colorectal cancer cells provided proof that the NuRD complex binds to 
promoters of several tumour suppressor genes together with DNA methyltransferases to 
maintain their silencing 122.  Such evidence emphasizes the role of NuRD in tumorigenesis. 
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5.5 Knockdown of MTA2 supported tumour growth 
Next, it was of interest to examine the effect of MTA2 silencing on tumour growth in 
vivo. Mice were injected subcutaneously with LLC1-shMTA2, LLC1-IKK2CA and LLC1-EV. 
Tumours of LLC1-shMTA2 were the biggest in size followed by those formed by LLC1-IKK2CA. 
Furthermore, a set of examined NF-ƙB target genes (Tnf, Nfkbia, Mmp9, Ccnd1, Cdkn1a and 
Cdkn1b) was upregulated on transcriptional level in the tumours of LLC1-IKK2CA and even 
more in LLC1-shMTA2. This observation goes in concordance with the in vitro studies 
showing a repressing effect of MTA2 on the activity of NF-ƙB and the expression of its target 
genes. A possible explanation would be that knocking down MTA via shRNA released the 
repressive effect on NF-ƙB and thus promoted tumour growth. MTA2 knock down also 
upregulated IKK2 expression though it isn’t a target gene of NF-ƙB suggesting that MTA2 
might play a role in the overall NF-ƙB activation.  
Though there are not many publications showing the effect of silencing of MTA2 on 
tumour growth, Lu et al. showed that shMTA2 reduced both primary and metastatic tumour 
growth in a human breast cancer model with MDA-MB231 cells123. This opposing effect to 
that observed in our lung tumour model inclines that different cellular scenarios might exist 
and that more experiments are required to fully unravel the underlying mechanisms of 
MTA2 regulation of tumorigenic processes. Other studies showed that MTA2 promoted 
cancer progression via the repression of tumour suppression genes like p5375 or through the 
repression of E-cadherin expression mediated by TWIST oncogene and thus driving the cell 
towards a mesenchymal fate96. 
 
5.6 Impact of genetic changes in epithelial host cells on the immune cell repertoire 
The genetic changes in host epithelial cells affect the cross-talk between host cells and 
their surrounding milieu. Especially in tumours, the role of the microenvironment was 
recently started to gain more attention in different cancer types124.   
5.6.1 In SpC C-Raf BxB mouse model 
The immune cell repertoire in SpC C-Raf BxB was studied in reference to IKK2 
modulation. IKK2 downregulation within SpC C-Raf BxB lungs reduced the infiltration of 
neutrophils, T cells, macrophages and dendritic cells compared to lungs with IKK activation. 
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This goes in concordance with the publication of Perez-Nazario et.al. who showed that host 
epithelial IKK2-dependent responses are important regulators of pulmonary adaptive 
immune responses44.  Macrophages are the main phagocytic cells that would attack tumour 
cells. However, these changes in the tumour microenvironment could not explain the 
restricted tumour growth in SpC/IKK2DN/BxB suggesting that both the signalling changes 
within the host alveolar type II cells as well as the tumour microenvironment intricately 
control tumour development. 
5.6.2 In xenograft model 
Flow cytometric analysis revealed the impact of the immune tumour microenvironment 
on tumour growth (Fig.4.24). Pro-tumorigenic B lymphocytes were abundantly present in 
LLC1-shMTA2 cells. Other immune cells which are known to be anti-tumorigenic, like 
cytotoxic natural killer cells and CD8+ T-lymphocytes, were both less represented in tumours 
from both IKK2CA and shMTA2. Interestingly, CD4+ cells which are responsible for the balance 
between the two T-helper cell populations, TH1 and TH2, were also less in the bigger tumours 
suggesting that the balance was probably shifted towards the pro-tumorigenic TH2. A similar 
tendency was observed with T regulatory cells which though supposed to act as pro-
tumorigenic but their presence is often correlated with better patient survival125.  
Most interestingly was the analysis of macrophages and their subtypes. MHC-II+ tumour-
associated macrophages (TAMs) are considered as M1-like macrophages which are anti-
tumorigenic, whereas MHC-II- TAMs are generally accepted to be pro-tumorigenic M2-like 
macrophages126.  In the subcutaneous tumour of LLC1-shMTA2 and LLC1-IKK2CA there were 
more MHC-II- TAMs and less MHC-II+ TAMs compared to control cells.  
Nevertheless, it is still debatable that MTA2 is often overexpressed in tumours and is 
thus correlated with poor prognosis in several cancer types. There is a possibility that there 
is a negative feedback loop that recruits more MTA2 together with the NuRD complex to 
suppress the activity of NF-ƙB. As most cancers retain a sustained activation of NF-ƙB, more 
MTA2 is needed to tightly control excessive activation and is thus recruited to NF-ƙB 
promoter binding sites leading to expressional repression.   
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5.7 NF-ƙB in epigenetic regulation 
Owing to its seminal role many biological processes, NF-ƙB is regulated at different 
levels, e.g. by binding to IƙB to stay in the cytoplasm, by post-translational modifications like 
phosphorylation and acetylation and also by epigenetic modifications. Zhong et al. 
demonstrated that p50 homodimers bind to HDAC1 in resting unstimulated conditions. Once 
appropriately stimulated, phosphorylated p65 translocates to the nucleus, associates with 
CBP and displaces p50-HDAC1 complex from the promoter region leading to expression of 
target genes127. 
Methylation and demethylation processes also play a role in transcriptional activation. 
Pacaud et al. could show that DNA (cytosine-5)-methyltransferase 3-like protein (DNMT3L) 
forms a complex with DNMT3B and NFkB-p65 at the TRAF1 promoter in the T98G glioma cell 
line. Higher expression of TRAF1 was observed in cells treated with siRNA against DNMT3L 
and p65 was recruited to the promoter indicating the role of p65/DNMT3L complex in the 
control of DNA methylation at TRAF1 promoter128.  
These studies provide evidence of the tight epigenetic control by and on the NF-ƙB 
complexes. MTA2/NuRD interaction with NF-ƙB can define new regulatory mechanism.  
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5.8 Conclusion 
In this work, the role of NF-ƙB activation via IKK2 in lung cancer was studied in vitro and 
in different preclinical models of lung cancer. Downregulation of IKK2 and subsequent 
interruption of NF-ƙB activation showed tumour inhibitory effects both directly in host cells 
as well as indirectly through manipulation of the tumour microenvironment. Interfering with 
upstream regulators of NF-ƙB usually resulted in many off-target effects making this 
approach disadvantageous for cancer therapy. Instead, this study attempted a deeper 
insight into the differential regulation of NF-ƙB signalling via MTA2/NuRD complex. Reporter 
activity assays, localization studies as well as the expression profile of NF-ƙB target genes 
confirmed the interaction of MTA2/NuRD complex with p50/p65 leading to the repression of 
NF-ƙB signalling. 
Nevertheless, it is still intriguing how MTA2 is often overexpressed in tumours and is 
thus correlated with poor prognosis in several cancer types and it represses NF-ƙB which is 
also aberrantly activated in most cancers. In vivo there are several factors contributing to the 
overall process of tumorigenesis. Our model posits that MTA2 might have a biphasic role in 
cancer. Increased growth and inflammatory stimuli activate NF-ƙB signalling pathway and 
thus switching on both positive and negative feedback loops. Excessive activation of NF-ƙB in 
cancer cells is accomplished via the formation of new cytokines and cell growth signals. At 
the same time tight regulatory mechanisms are mediated as well through the expression of 
negative regulators, e.g. IƙB proteins, and through recruitment of MTA2/NuRD complex to 
NF-ƙB target genes poising their expression. With persistent activation of NF-ƙB in cancer 
cells, more MTA2 is produced and recruited to respective promoters attempting to constrain 
excessive activation (Fig. 5.1). This overall balance determines the final fate of the cells; in 
normal cellular context the activating signal is attenuated, whereas in cancer cells a 
continuous activation overcomes the tight control mechanisms. 
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Figure  5.1 Recruitment of MTA2 to NF-ƙB target genes. a) Cytokines and cellular stimuli activate IKK2 to drive 
nuclear translocation of p50/p65, b) active transcription of various NF-ƙB target genes that support tumour 
growth, c) tumour niche produces more cytokines that further activate NF-ƙB signalling, d) excessive 
upregulation of NF-ƙB recruits MTA2/NuRD complex to promoter region of NF-ƙB target genes, e) MTA2/NuRD 
binds to p50/p65 preventing its transcriptional activity.    
 
In conclusion, NF-ƙB signalling pathway plays a crucial role in tumour development but it 
is also seminal for maintaining homeostasis. Direct interference with this pathway was to 
date not satisfactory on therapeutic level. Thus, studying the role of its intricate regulation 
via MTA2/NuRD complex might provide useful insight into new therapeutic modalities 
targeting the binding of MTA2 and p50/p65 to each other. Yet, more research is required to 
delineate the dynamics of this interaction and its specificity within different cellular 
scenarios.   
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6 Future Perspectives  
Lung cancer is a major challenge stressing a relatively large set of the world population. 
It is a multifactorial disease controlling several vital processes and the hitherto existing 
treatment regimens are faced with limited success. Thus there is a compelling need to 
develop novel but more specific therapies which require a deeper insight into the molecular 
background within the cancer cells. 
Increasing evidence emphasize the role of NF-ƙB in tumorigenesis. Our work clearly 
showed that IKK2 can regulate tumour growth and metastasis and that MTA2/NuRD complex 
regulates NF-ƙB. The identified interaction between p50/p65 and MTA2/NuRD complex can 
be extended to map for their specific interaction domains. This can be attempted by 
generation of domain deletion variants and analysing their capability of interaction. Such 
data would be beneficial in targeting the interaction by synthesis of domain specific peptides 
that would compete with the fully functional proteins and thus hamper the repressing 
activity of MTA2.  
Moreover, both MTA2/NuRD and NF-ƙB family members are capable of forming 
different complexes suggesting the possible formation of a horde of coexisting complexes 
with differential activity. Identification of these complexes via mass spectrometry would 
help in the understanding of the disparity of responses observed in cancer versus normal 
cells. It would be of benefit to investigate the interaction and its kinetics in other solid 
tumours such as breast cancer and hepatocellular carcinoma. 
Using the existing high throughput platforms, like ChIP-Seq and RNA Seq, it would be 
possible to identify specific target genes and their respective specific MTA2-binding motifs. 
This would aid in understanding the paradoxical effects of MTA2/NuRD complex reported in 
several cancer types. 
Understanding these underlying mechanisms combining a crucial inflammatory 
regulator, NF-ƙB, with the NuRD complex as an essential chromatin remodelling complex, 
holds great promises for the developing of novel intervention tools in cancer management.  
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7 Summary 
Inflammation and cancer have been linked more than a century ago when Rudolf 
Virchow identified leukocytes infiltration in neoplastic tissues. Many years of research 
followed until the discovery of NF-ƙB, which paved the way to more insight into the 
contribution of inflammatory signalling to cancer development. NF-ƙB is not only involved in 
many innate and adaptive immune responses but also governs the expression of wide set of 
diverse genes regulating cell growth and adhesion, cell cycle regulation, apoptosis, 
angiogenesis – all established hallmarks of neoplastic transformation. Many tumours, 
especially solid tumours, exhibit constitutive activation of NF-ƙB canonical signalling 
pathway. This fact encouraged several researchers to develop NF-ƙB inhibitors and IKK2 
inhibitors as adjunct therapy to existing cancer treatment modalities, however, with modest 
success. More studies are required for a better understanding of NF-ƙB activation in cancer 
and the underlying regulatory mechanisms.  
In this work, NF-ƙB canonical signalling was studied in lung adenocarcinoma cell lines 
and animal model. Chemical stimulation of various adenocarcinoma cells lines (A549, A427, 
Colo699, H1650, and H2122) as well as non-tumour cell lines (BEAS-2B and HEK) with LPS 
and TNFα induced NF-ƙB nuclear translocation and subsequent activation. The functional 
effects of NF-ƙB activation were reflected in increased proliferation and migration. Specific 
IKK2 inhibitors like sc-514, parthenolide or Bay11-7085 as well as proteosomal inhibitor like 
MG-132 showed opposed effects indicating that the pivotal role of IKK2 activation in cancer 
cells. In corroboration, genetic mouse model where IKK2 was specifically constitutively 
activated or downregulated in SPC-expressing epithelial alveolar type II cells (SpCrtTA/Tet-O-
IKK2CA/SpC Ca-Raf BxB and SpCrtTA/Tet-O-IKK2DN/SpC Ca-Raf BxB, respectively) led to 
significant alterations in tumour development. Downregulation of IKK2 decreased the 
tumour dispersion in the lung and improved lung function. Furthermore, IKK2 changes in 
host epithelial cells also affected the immune cell repertoire significantly in the tumour 
microenvironment. 
Importantly, mouse epithelial alveolar type II cells expressing IKK2DN compared to 
wildtype cells regulated several genes that didn’t possess any known NF-ƙB consensus 
sequences in their promoters. Among these genes was metastasis-associated protein family 
member 2, known as MTA2. Further examination of MTA2 expression on protein level in 
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different cells lines suggested that cell lines originating from metastatic sites showed higher 
expression of MTA2 than those isolated from primary sites. Surprisingly, MTA2 was not 
upregulated in response to NF-ƙB stimulation, but regulated in response to IKK2 
downregulation (IKK2DN or IKK2 inhibitor treatment). 
MTA2 is reported as a member of the NuRD complex (consisting of MBD1/2, HDAC1/2, 
CHD3/4, GATA2Da/b, and RbAp46/448) that regulates gene expression at a transcriptional 
level. Indeed, MTA2 overexpression decreased NF-ƙB activity and the expression of a wide 
set of NF-ƙB target genes. Interestingly, our results indicated the presence of MTA2 together 
with other members of the NuRD complex and NF-ƙB heterodimer p50/p65 as assessed by 
fractionation, immunoprecipitation and proximity ligation assay studies. Finally, ChIP assay 
could identify MTA2 and RbAp46 in the promoter region of NFKB1 and NFKBIA, a target gene 
of NF-ƙB. These data taken together support the hypothesis that MTA2 as part of NuRD 
complex binds to NF-ƙB and its target genes to regulate their expression.  
Finally, MTA2 was knocked down in LLC1 cells via shRNA and injected into C57Bl/6J mice 
subcutaneously. Tumours with shMTA2 were bigger in size compared to tumours from LLC1 
control or even to LLC1-IKK2CA. Even their immune repertoire shifted towards a tumour-
favouring signature with more M2-like macrophages and less cytotoxic T-lymphocytes. 
In summary, this work suggests MTA2 as regulator of NF-ƙB signalling pathway in lung 
cancer. Increased NF-ƙB activity leads to the expression of several cytokines that continue 
activating the pathway. A poised mechanism to tightly regulate NF-ƙB recruits MTA2/NuRD 
complex to cardinal NF-ƙB target genes repressing their transcription. The proposed 
mechanism still needs more research to elucidate the exact kinetics of this feedback loop 
regulation. 
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8 Zusammenfassung 
Seit dem letzten Jahrhundert, als Ruldof Virchow Leukozyten in Tumoren entdeckt hat, 
werden Tumorbildung und Entzündungsprozessen zusammengeknüpft. Viele Jahre der 
Forschung folgten bis zur der Entdeckung von NF-ƙB. Nuklear Faktor kappa B (NF-ƙB) ist ein 
wichtiger Transkriptionsfaktor für das Immunsystem und die Regulation von 
Entzündungsprozessen. Es gibt bereits mehrere Publikationen, die die Dysregulation von NF-
ƙB in unterschiedlichen Krebsarten zeigen. Dennoch fehlt der Mechanismus dieser 
Regulation, der vor allem durch die aktivierende Kinase IKK2 (Inhibitor kappa B kinase beta) 
vorgeht.  
In der vorliegenden Arbeit wurde der klassische Signalweg von NF-ƙB in Lungenkrebs-
Zelllinien und anhand von Tiermodellen untersucht. Chemische Stimulation der Tumor-
Zelllinien (A549, A427, Colo699, H1650, und H2122) als auch der Kontrollzelllinien (BEAS-2B 
and HEK) durch LPS und TNFα führte zur Translokation von p50/p65 zum Zellkern. Die darauf 
folgende Aktivierung der Transkription verschiedener Gene spiegelte sich in zunehmender 
Proliferation und Migration der Zellen. Spezifische IKK2 Inhibitoren wie sc-514, parthenolide, 
Bay11-7085 und MG-132 haben diesen Prozess gehemmt. Diese Ergebnisse wurden in einem 
Tiermodell bestätigt, wo modifiziertes IKK2 unter dem SPC –Promotor zusammen mit C-Raf 
BxB in alveolaren Epithelzellen exprimiert wurde (SpC rtTA/Tet-O-IKK2CA/SpC C-Raf BxB and 
SpC rtTA/Tet-O-IKK2DN/SpC C-Raf BxB). Die Runterregulation von IKK2 beschränkte die 
Tumorbildung, wie durch MRT und histologische Untersuchung zu erkennen war, und 
verbesserte damit die Lungenfunktion. Darüber hinaus haben die Veränderungen in IKK2-
Aktivierung die Immunzellpopulation der Tumorumgebung beeinflusst. 
Maus Epithelzellen (ATII) wurden aus Wildtyp-Tieren und  SpC rtTA/Tet-O-IKK2DN-Tieren 
isoliert. Durch den Vergleich der unterschiedlich exprimierten Gene wurde eine Gruppe von 
Genen identifiziert, die von IKK2DN beeinflusst wurden, obwohl sie keine NF-ƙB Konsensus-
Sequenz erweisen. MTA2, metastasis-associated protein family member 2, gehörte zu dieser 
Gruppe.  
Andere Studien haben gezeigt, dass MTA2 in Nichtkleinzelligem Lungenkrebs 
hochreguliert wird und mit den Krebsstadien korreliert. Die Protein-Expression von MTA2 
war in den Lungenkrebs-Zelllinien, die aus Metastasen stammen, höher exprimiert als in den 
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Zelllinien, deren Herkunft Primärtumore ist. MTA2 gehört zu dem NuRD (Nucleosome 
Remodelling Deacetylase)-Komplex. Dieser Komplex besteht aus mehreren Proteinen, u.a. 
die MTA (Metastasen-assoziierten Proteinen)-Familie (MTA1, MTA2 oder MTA3). In der 
vorliegenden Studie wurde gezeigt, dass MTA2 Überexpression eine repressive Wirkung auf 
einige NF-ƙB-Zielgene ausübt. Außerdem wurde eine Interaktion zwischen p50/p65 und 
MTA2/NuRD durch Immunoprecipitation, PLA (proximity ligation assay) und die 
Fraktionierung nuklearer Komplexe bestätigt. ChIP-Experimente wiesen MTA2 und RbAp46 
in den Promotorregionen von NFKB1 und NFKBIA (bekannte NF-ƙB-Zielgene) nach. Dies 
unterstützt unsere Hypothese, dass MTA2/NuRD-Komplex NF-ƙB-Zielgene reguliert. 
Zum Schluss wurden LLC1 Zellen, die shMTA2 und IKK2CA exprimieren, in subkutanem 
Tumormodell injiziert. Tumore mit blockierten MTA2 (shMTA2) waren mächtiger und zeigten 
eine tumorfördernde Immunzellumgebung.  
Zusammenfassend schlägt die vorliegende Arbeit MTA2 als Regulator von NF-ƙB vor, 
und stellt damit einen neuen Ansatz für Therapieentwicklung. Mehr Forschung ist dennoch 
erforderlich, um den biologischen Kontext und die genaue Kinetik der Regulation zu 
definieren.    
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9 Appendix 
9.1 Appendix I: List of Antibodies 
Table  9.1 Antibodies used for Western blotting (WB) 
Antibody Host Dilution Company (Catalogue 
Number) 
CHD4 Mouse 1:1000 Abcam (ab70469) 
Cyclin D1(92G2) rabbit 1:1000 Cell Signalling (2978) 
HDAC1 Rabbit 1:1000 Abcam (ab7028) 
HDAC2 Rabbit 1:1000 Abcam (ab16032) 
IƙB (44D4) Rabbit 1:1000 Cell Signalling (4812) 
MTA2 Rabbit 1:200 Abcam (ab8106) 
NF-ƙB  p105/p50 [E381] Rabbit 1:1000 Abcam (ab32360) 
NF-ƙB p65 (C-20) Rabbit 1:200 Santa Cruz (sc-372) 
p300 (N-15) Rabbit 1:200 Santa Cruz (sc-584) 
RbAp46 (N-19) Goat 1:200 Santa Cruz (sc-8272) 
ß-actin [AC-15] Mouse 1:3000 Abcam (ab6276) 
 
Table  9.2 Antibodies used for Immunocytochemistry (ICC) & Proximity ligation assay (PLA) 
Antibody Host Dilution Company  
(Catalogue Number) 
MTA2 Rabbit 1:200 Abcam (ab8106) 
NF-ƙB p50 (NLS) Rabbit 1:200 Santa Cruz (sc-114) 
NF-ƙB p65 (C-20) Rabbit 1:200 Santa Cruz (sc-372) 
NF-ƙB p-p65 (A-8) Mouse 1:200 Santa Cruz (sc-166748) 
Surfactant protein C Rabbit 1:1000 Millipore (AB3786) 
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Table  9.3 Antibodies used for Immunohistochemistry (IHC) & Immunofluorescence (IF) 
Antibody Host Dilution Antigen 
retrieval 
Company 
(Catalogue Number) 
CD11b [EP1345Y] Rabbit 1:100 Trypsin Abcam (ab52478) 
CD3 Mouse 1:200 EDTA Dako(M7254) 
IKK2 (P-20) Goat 1:200 Citrate Santa Cruz (sc-34673) 
MMP9 (C-20) Goat 1:200 Citrate Santa Cruz (sc-6840) 
MTA2 Rabbit 1:200 Citrate Abcam (ab8106) 
NF-ƙB p50 (NLS) Rabbit 1:200 Citrate Santa Cruz (sc-114) 
NF-ƙB p65 (C-20) Rabbit 1:200 Citrate Santa Cruz (sc-372) 
NF-ƙB p-p65 (A-8) Mouse 1:200 Citrate Santa Cruz (sc-166748) 
PCNA (FL-261) Rabbit 1:200 Citrate Santa Cruz (sc-7907) 
Raf-1 (C-Raf; C-20) Rabbit 1.200 Citrate Santa Cruz (sc-227) 
 
Table  9.4 List of Secondary antibodies 
Antibody Dilution Application Company (Catalogue 
Number) 
Alexa Fluor® conjugates 1:1000 ICC, IF Invitrogen, Molecular Probes 
Anti-mouse IgG HRP 
conjugate 
1:3000 WB Promega (W4028) 
Anti-rabbit IgG HRP conjugate 1:3000 WB Promega (W4018) 
Bovine anti-goat IgG HRP 1:3000 WB Santa Cruz (sc-2378) 
Normal rabbit IgG 1µg/0.2x106 cells ChIP Santa Cruz (sc-2027) 
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9.2 Appendix II: List of Primers 
Table  9.5 List of primers used for quantitative real time PCR (Mus musculus) 
Gene Primer Sequence (5’-3’) Annealing  temperature Accession Number 
Ccnd1 FP: ATGAACTTCACATCTGTGGCA 
RP: CCCCACGATTTCATCGAACA 58 
NM_007631.2 
Cdkn1a FP: TGGTGTCTGAGCGGCCTGAA 
RP: GCCTCCTGACCCACAGCAGA 58 
NM_001111099.1 
Cdkn1b FP: AATCCGGCTGGGTTAGCGGA       
RP: TCTTGGGCGTCTGCTCCACA 58 
NM_009875.4 
Chuk FP: aTGCCTGTACACAGAGTTCTGCCC 
RP: TCACACATGTCAGAGGATGTTCACG 58 
NM_001162410.1 
Fn1 FP: TGGATAGCACCCAGTGTTCAG 
RP: CCTGTCTTCTCTTTCGGGTTCA 58 
NM_010233.1 
Hprt FP: GCTGACCTGCTGGATTACAT 
RP: TTGGGGCTGTACTGCTTAAC 58 
NM_013556.2 
Ikbkb FP: AGAAAAGTGAAGAACTGGTGGCCG 
RP: CCCTCAGGCGGTTACCGTGA 58 
NM_001159774.1 
Mmp9 FP: ACGGGTATCCCTTCGACGGC 
RP: AGTGGGGATCACGACGCCTTT 58 
NM_013599.2 
Mta1 FP: ACCAGTGGTATTCTTGGGGT 
RP: GTGGGGACTCATGTTACTGC 58 
NM_054081.2 
Mta2 FP: TCCCACCTACACTAAGCCAA 
RP: GTGGCAACTCTCACAAGTCA 58 
NM_011842.3 
Mta3 FP: TCCCAACCTACAAACCAAATCC 
RP: TTAGGTGGGCCCCAAGAATA 58 
NM_001171053.1 
Myc FP: CCCACCCGCCCTTTATATTCC 
RP: GTCCTGGCTCGCAGATTGTA 58 
NM_010849.4 
Ncam1 FP: GCAGTTTACAATGCTGCGAA 
RP: CATCTCCTGCCACTTGACAC 58 
NM_001081445.1 
Nfkb1 FP: AGGGGTCACCCATGGCACCA 
RP: TGCCAAGGCGATGGGTTCCG 58 
NM_008689.2 
Nfkbia FP: GCTACCCGAGAGCGAGGAT 
RP: GCCTCCAAACACACAGTCATCAT 58 
NM_010907 
Rela FP: TGATAACCGGGCCCCCAA 
RP: CTGCACCTTGTCGCACAG 58 
NM_009045.4 
Tert FP: CGGACAAAACATCCTCACCT 
RP: CGGTCACATCTGCCTTAACA 58 
NM_009354.1 
Tnf FP: CAGGCGGTGCCTATGTCTC 
RP: CGATCACCCCGAAGTTCAGTAG 60 
NM_013693.2 
Twist1 FP: GGACAAGCTGAGCAAGATTCA 
RP: CGGAGAAGGCGTAGCTGAG 58 
NM_011658.2 
Vegfc FP: ACCTCCATGTGTGTCCGTCT 
RP: TTCAAACAACGTCTTGCTGAGG 58 
NM_009506.2 
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Table  9.6 List of primers used for quantitative real time PCR (Homo sapiens) 
Gene Primer Sequence (5’-3’) Annealing  temperature Accession Number 
FN1 FP: ATTACTGGCCTGGAACCGGGA 
RP: ACCAGTTGGGGAAGCTCGTCT 60 
NM_002026 
HPRT FP: TGACACTGGCAAAACAAT 
RP: GGTCCTTTTCACCAGCAA 58 
 
MMP9 FP: CGGAGCACGGAGACGGGTAT 
RP: GAGTTGGAACCACGACGCCC 58 
NM_004994 
MTA1 FP: ACCAGTGGTATTCTTGGGGT 
RP: GTGGGGACTCATGTTACTGC 58 
NM_004689.3 
MTA2 FP: TCCCACCTACACTAAGCCAA 
RP: GTGGCAACTCTCACAAGTCA 58 
NM_004739.3 
NFKB1 FP: GCCACCCGGCTTCAGAATGG 
RP: GGCCATCTGCTGTTGGCAGT 60 
NM_003998.3 
RELA FP: GCAGTGTTGGGGGCACGATT 
RP: AGAGCAGCGTGGGGACTACG 58 
NM_021975.3 
 
Table  9.7 List of primers used for genotyping by qualitative PCR 
Genotype Primer Sequence (5’-3’) Annealing temperature 
Amplicon 
size (bp) 
SpC C-Raf BxB SPC S1: GAG GAG AGG AGA GCA TAG CAC C 
BXB : ACA TCT CCG TGC CAT TTA CCC 60 400 
SpC rtTA SPC USA: GAC ACA TAT AAG ACC CTG GTC A 
rtTA USA: AAA ATC TTG CCA GCT TTC CCC 58  
Tet-O-IKK2EE  
(IKK2CA) 
pBI5: GGT ACC CGG GGA TCC TCT AGT CAG 
IKK2-rev1: GGT CAC TGT GTA CTT CTG CTG CTC 
CAG 
63 672  
Tet-O-IKK2DN 
(IKK2DN) 
pBI5: GGT ACC CGG GGA TCC TCT AGT CAG 
IKK2-rev1: GGT CAC TGT GTA CTT CTG CTG CTC 
CAG 
63 822 
 
Table  9.8 List of ChIP primers 
Gene Primer Sequence (5’-3’) Annealing  temperature Binding site 
NFKB1 Proximal FP: GAC GTC AGT GGG AAT TTC C 
Proximal RP: GTG GCG AAA CCT CCT CTT C 58 -28 
NFkB1 Upstream FP: TGC TGC ATG GAA TTA CAT CC 
Upstream RP: CAT CTT AAC TTG ATA ACA TTT GC 58 -2341 
NFKBIA FP: GAC GAC CCC AAT TCA AAT CG 
RP: TCA GGC TCG GGG AAT TTC C 58 -342 
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9.3 Appendix III: List of Buffers 
Table  9.9 Buffers used for chromatin immunoprecipitation (ChIP) 
Buffer Composition 
L1 lysis buffer 50 mM Tris.HCl pH 8 
2 mM EDTA pH 8 
0.1% NP40 (IGEPAL instead) 
10% Glycerol 
L2 nuclear resuspension buffer 50 mM Tris.HCl pH 8 
5 mM EDTA pH 8 
1% SDS 
Dilution buffer (DB) 50 mM Tris.HCl pH 8 
5 mM EDTA pH 8 
0.5% NP40 
0.2 M NaCl 
Low salt washing buffer 20 mM Tris.HCl pH 8 
2 mM EDTA pH 8 
1% NP40 (IGEPAL instead)  
0.1% SDS 
0.15 M NaCl 
High salt washing buffer 20 mM Tris.HCl pH 8 
2 mM EDTA pH 8 
1% NP40 (IGEPAL instead)  
0.1% SDS 
0.5 M NaCl 
LiCl washing buffer 10 mM Tris.HCl pH 8 
1 mM EDTA pH 8 
1% NP40 (IGEPAL instead)  
1% Na-deoxycholate 
0.25 M LiCl 
TE buffer 10 mM Tris.HCl pH 8 
1 mM EDTA pH 8 
C1 DNA elution buffer 10 mM Tris.HCl pH 8 
1 mM EDTA pH 8 
0.1 M NaHCO3 
1% SDS 
DNA elution TE buffer 25 mM Tris.HCl  
1 mM EDTA pH 10 
 
 
 
 
 
Appendix 
97 
 
Table  9.10 Buffers used for immunoprecipitation (Co-IP) and nuclear fractionation 
Buffer  Composition 
Co-IP buffer 50mM Tris pH7.4 
15mM EGTA 
100mM  NaCl 
0.1% (v/v) TritonX-100 
Modified cell lysis buffer 10mM Tris pH7.4 
1.5mM MgCl2 
10mM KCl 
0.1% TritonX-100 
1mM EDTA 
2x SDS PAGE sample application buffer 150mM Tris pH6.8 
1.2% SDS 
30% glycerol 
6.7% ß-mercaptoethanol 
1.8mg bromophenol blue 
Hypotonic lysis buffer 10mM Tris HCl pH 7.4 
1.5 mM MgCl 
10mM KC 
Native nuclear lysis buffer 0.2% IGEPAL 
100mM NaCl 
50 mM Tris HCl pH 7.0 
1mM EDTA 
 
 
Table  9.11 Buffers used for SDS-PAGE & immunoblotting 
Buffer Composition 
10x SDS PAGE running buffer 35mM SDS 
250mM Tris 
0.86M glycin 
Blotting buffer 25mM Tris  
192mM glycine 
20% methanol 
5x SDS PAGE sample application buffer 1.5M Tris-HCl pH 6.8  
10% SDS  
50% glycerol 
25% ß-mercaptoethanol  
0.01% bromophenol blue  
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